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1 Introduction 
This study comprises two experimental approaches.  
1. Further investigation towards a whole-organism vaccine against malaria 
by inhibiting the prokaryotic organelle within the malaria parasite using 
bacteriostatic antibiotics. 
2. Effectiveness of drugs conjugated to the hepatitis B virus derived surface 
PreS protein. Eventually regarding liver specific delivery for the usage in 
whole organism vaccinations as well as an extended application possibility 
of these drugs. 
 Epidemiology of malaria and its impact on global health 
Although malaria can be cured easily and both incidence and mortality are 
declining due to improved access to medical care and interventions, it still is a 
great global health burden: every two minutes a child dies of malaria - 720 of the 
youngest every day (WHO, 2017). 
The world health organisation (WHO) declares in their annual report of 2018: 87 
countries suffer from malaria transmission – over 3 billion people live at risk to be 
infected. In 2017, around 219 million cases were reported while the disease cost 
the life of 435.000 people, 61% of them children aged under 5 years (WHO, 
2018). 
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Figure 1. World distribution of malaria in 2014 (WHO, 2014).The majority of 
malaria cases occur in sub-Saharan Africa while South America and parts of Asia also 
suffer from the disease.   
Malaria occurs in the tropics and subtropics while mainly sub-Saharan Africa is 
affected, with 92% of reported cases in 2017 occurred in the WHO African, 5% in 
the Southeast Asian and 2% in the Mediterranean region (WHO, 2018). 
 
 Malaria parasites and life cycle 
Malaria is caused by a unicellular eukaryotic endoparasite. It uses the human 
being as an intermediate host plus the female Anopheles mosquito as both, a 
vector and host, to fulfil its complex life cycle.  
1.2.1 Human pathogen Plasmodium species 
Malaria-causing parasites belong to the genus Plasmodium, which includes 
about 200 species. Amongst them are five human pathogen parasites, namely P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. 
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Infections with these five human malaria parasites are associated with distinct 
clinical manifestations. These species also display different geographical 
distributions. 
P. vivax occurs to 83% outside of Africa where it is the most common cause of 
malaria (WHO, 2016). It uses the Duffy-antigen on the host’s erythrocytes to enter 
them. The loss of this antigen is a widespread natural immunity on the African 
continent which results in a lower burden of P. vivax infections there (Culleton et 
al., 2008). 
P. falciparum is the dominant malaria parasite in Africa. It claims the majority 
(99%) of lives while 90% of all deaths occur on the African continent.  
In this introduction, I focus on P. falciparum being the main human health threat. 
However, the data was partly collected using P. berghei, a rodent malaria 
parasite, as a model system. Since the aim of the study concerns the biology of 
Plasmodium species in general, this model represents a safe, well-established 
and suitable method to undertake these experiments. 
1.2.2 Life cycle of human pathogen Plasmodium parasites 
To pursue its transmission, the Plasmodium parasite depends on the female 
Anopheles mosquito as a vector and host plus a mammalian intermediate host. 
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Figure 2. Plasmodium life cycle; modified after Hill (Hill, 2011). When an 
infected mosquito bites a mammalian host, up to 100 so-called sporozoites are delivered 
into the skin. They reach the liver, multiply, break out and invade erythrocytes. Only the 
massive replication of blood stages causes the typical flu-like symptoms of malaria like 
chills, headache, fever and fatigue. 
Exo-erythrocytic stage 
During a blood meal of the female Anopheles mosquito, up to a few hundred 
sporozoites are deposed in the skin tissue of the mammalian host. Sporozoites 
actively move and penetrate into local blood capillaries and from there, are 
passively delivered via the blood circulation to the liver (Medica and Sinnis, 2005, 
Amino et al., 2006). 
In the liver, sporozoites glide inside the liver sinusoids along the hepatocytes and 
finally, invade hepatocytes after passing through resident Kupffer cells. Even 
after reaching a hepatocyte, sporozoites continue passing through several cells 
until settling down in a suitable cell and start forming a parasitophorous vacuole 
for further development (Pradel and Frevert, 2001, Frevert et al., 2005, Mota et 
al., 2001). Subsequently, the sporozoites differentiate and undergo schizogony: 
 
 
 
104 
1012 
 102 
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they asexually build up a polyploid cell (schizont) by DNA replication. Nuclear 
division takes place only after multiple rounds of DNA replication (Striepen et al., 
2007, Gerald et al., 2011). Eventually, daughter cells are build up: out of one 
single sporozoite up to 104 invasive blood stages, so-called merozoites, are 
formed (Sturm et al., 2009). Thereupon, merozoites emerge from the liver via a 
vesicle (merosome). These vesicles consist of 100-200 merozoites and bud off 
the detached host cell, probably allowing the parasite to hide from the host’s 
immune system (Sturm et al., 2006, Baer et al., 2007). These merosomes reach 
the bloodstream and are transported to the capillaries of the lung, where they 
egress, hence releasing infectious merozoites (Baer et al., 2007). In the case of 
P. falciparum, the asymptomatic liver stage can take up to 8 days. 
 
 
Figure 3. Ruptured merosome of in vitro cultured P. berghei in Huh7 cells. 
Representative micrograph (scale bar: 10 µm). Hoechst (blue) was applied for DNA 
staining, anti-HSP70 antibody to stain the parasite itself, appears green and anti-acyl 
carrier protein (ACP) antibodies to stain the apicoplast organelle inside the parasite (red). 
Note the several single merozoites emerged out of the vesicle. See experimental details 
further below. 
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Intra-erythrocytic stage 
After their release, merozoites rapidly detach to and invade red blood cells, 
thought to minimise antigen stimulation of the host’s immune system. Crucial for 
this invasion of host cells is the apical complex, containing a collection of 
specialised subcellular structures within the parasite. This complex is also 
present in other human pathogen parasites like Toxoplasma gondii or 
Cryptosporidium parvum. Indeed, the name of the phylum Apicomplexa stems 
from this unique structure (Cowman and Crabb, 2006, Arisue and Hashimoto, 
2015). 
After invasion, Plasmodium falciparum parasites undergo several replication 
cycles with a duration of 48 hours each, passing through different, microscopically 
distinguishable stages of development (ring stage – trophozoite stage – schizont 
stage – merozoites). Each cycle produces around 10-20 progeny, rapidly yielding 
enormous parasite loads of up to 1012 parasites.  
 
 
Figure 4. Developmental forms of blood stage parasites. During replication in 
erythrocytes, parasites undergo microscopically distinguishable differentiation. They turn 
from the first observed form, the ring stage (1) to trophozoites (early, 2 and late, 3) and 
subsequently to schizonts (4). Within schizonts, new daughter cells, so-called 
merozoites are formed (4). Finally, merozoites egress from the host cell (not shown) and 
re-invade new erythrocytes; hence start a new replication cycle. 
Whereas P. falciparum’s multiplication is not synchronised, the other human 
pathogen Plasmodium parasites multiply in a synchronised pattern, resulting in 
individual courses of disease defined by specific alternation of fever peaks and 
fever afebrile episodes. However, only P. falciparum infections can lead to severe 
malaria, characterised by coma, metabolic acidosis, severe anaemia, 
hypoglycaemia and renal failure. Cerebral malaria (with deep, unarousable coma 
(1) (2) (3) (4) 
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as the leading symptom) is thought to be due to micro-embolic infarcts owing to 
parasite-induced cytoadherence and sequestration of infected red blood cells in 
the deep vasculature of the brain (Miller et al., 2002, Alister et al., 2012). This 
serious scenario is likely associated with high case fatality ratio or in survivors, 
with disabling long-term health issues like neurological disorders.During 
multiplication of the parasites within erythrocytes, a variable proportion of ring 
stages start differentiating into sexual stages, called gametocytes. These female 
or male parasite stages are again taken up by female Anopheles mosquitos 
during a blood-sucking bite. Inside the mosquito’s midgut, exflagellated male 
gametocytes are able to fertilise female gametocytes and then turn into zygotes. 
 
 
Figure 5. Mosquito stage of the Plasmodium life cycle. Incorporated female and 
male gametocytes fertilise inside the midgut of female Anopheles mosquitos. They form 
diploid zygotes and further differentiate develop into ookinetes and meiosis begins. 
Ookinetes are actively able to access the midgut epithelia. They mature to oocysts 
producing motile sporozoites (haploid) which invade the salivary gland of the mosquito. 
Inside the vector’s or rather host’s midgut, the zygote differentiates into an 
actively moving ookinete and at the same time, initiates sexual replication 
(meiosis). After penetration of the midgut epithelium, the ookinete transforms into 
MG 
ZG 
OK 
OC 
SP 
SG 
ZG = zygote 
OK= ookinete 
MG = mid gut 
OC = oocyst 
SP = sporozoites 
SG = salivary gland 
Gametocyte of P. falciparum 
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an oocyst and completes meiosis. Asexual replication sets in, producing 
thousands of haploid, actively moving sporozoites via schizogony. Once 
sporozoites reach the salivary gland, female Anopheles mosquitoes are 
infectious for around 2-3 weeks, hence the transmission cycle starts again 
(Mueller et al., 2010).  
 The apicoplast of Plasmodium spp.  
As mentioned above, Plasmodium parasites belong to the phylum Apicomplexa. 
Not only do they share an eponymous apical complex, but most additionally share 
a mutual organelle, called apicoplast.  
This prokaryotic organelle derives from a chloroplast (which itself has its origin in 
a cyanobacterium) and is surrounded by four membranes. These findings 
suggest that the apicoplast entered the parasite via secondary endosymbiosis. 
 
 
Figure 6. Secondary endosymbiosis of the apicoplast (Striepen, 2011). In the 
beginning, a cyanobacterium was engulfed by a eukaryote cell. Thus, an alga arose, 
which itself merged with another eukaryotic host cell to form the common ancestor of 
apicomplexan parasites. 
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During the first endosymbiosis, a cyanobacterium was engulfed i.e., via 
phagocytosis, by a eukaryotic cell (probably a biciliate protozoan) around 1.5 
billion years ago – together forming the ancestor of all green algae and plants, 
red algae and glaucophytes. These cells were now able to generate energy 
through photosynthesis inside the cyanobacterium-derived organelle 
(chloroplast). The available genetic evidence then points to a secondary 
endosymbiosis event: a red alga was taken up in by another eukaryotic cell, 
giving rise to the phylum Apicomplexa. While apicomplexan parasites such as 
Plasmodium still harbour the prokaryotic plastid, it has lost its photosynthetic 
capacity (Lim and McFadden, 2010). 
1.3.1 Function of the apicoplast in Plasmodium 
 
The apicoplast still contains a 35 kb DNA genome coding for a few tRNAs and 
housekeeping proteins. However, most of the proteins required for its function 
and replication are encoded in the parasite’s nucleus and imported into the 
organelle. Because of the evolutionary history of the apicoplast, these proteins 
are either of prokaryotic origin (following the transfer of genes from the 
endosymbiont to the host cell nucleus) or of eukaryotic origin. Thus, the few 
biochemical pathways inside the apicoplast consist of a mosaic of enzymes of 
different evolutionary origin (Martin and Herrmann, 1998, Waller et al., 1998). 
Still, the parasite is not able to survive without the remnant, indeed the apicoplast 
harbours essential metabolic pathways on which the parasite depends 
throughout different stages during its life cycle (Ralph et al., 2004). Firstly, the 
heme biosynthesis pathway, which is essential during development in the 
mosquito and the liver is partially located inside the apicoplast (Ke et al., 2014, 
Rathnapala et al., 2017). Secondly, the organelle harbours the type II fatty acid 
synthesis which is crucial in the late liver stage development of the parasite (Yu 
et al., 2008). Additionally, during blood stage infection and especially, egress from 
the infected red blood cells, isopentenyl pyrophosphate (IPP) production within 
the plastid plays a key role (own data). Interestingly, supplementing solely IPP 
can fully compensate for the loss of the whole organelle in blood stage parasites 
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(Yeh and DeRisi, 2011). Hence, this relict plastid is essential for parasite survival 
(He et al., 2001). 
1.3.2 The apicoplast of Plasmodium as a target  
 
Every parasite hosts only one apicoplast which must be inherited vertically to 
every daughter cell during asexual replication in liver, blood and mosquito stages. 
Biogenesis of the apicoplast can be observed during schizogony as a branching 
structure, followed by fission at the end of a replication cycle and distribution into 
every descendant in a 1:1 fashion (Waller and McFadden, 2005). 
Direct inhibition of metabolic pathways located in the apicoplast, in other words 
targeting non-housekeeping processes, e.g. blocking of IPP production in blood 
stages via fosmidomycin induces an immediate parasiticidal effect (Missinou et 
al., 2002). 
On the other hand, using housekeeping functions of the apicoplast in blood stage 
parasites as a target results in a “delayed death”. This means that parasite 
proliferation is arrested at the end of the second cycle of replication in human 
erythrocytes, 96 hours after the start of the first cycle (Ramya et al., 2007). This 
can be achieved by applying bacteriostatic antibiotics. Bacteriostatic antibiotics 
stop bacteria in their metabolism but do not kill them, in contrast to bactericidal 
antibiotics. For example, bacteriostatic antibiotics like clindamycin, tetracycline or 
azithromycin bind and block prokaryotic ribosomes, targeting the apicoplast’s 
own translational machinery (Wilson et al., 1996). This seems to impede the 
organelle’s inheritance but does not kill it immediately, and thereby induce 
delayed death in blood stage parasites (Burkhardt et al., 2007, Dahl et al., 2006, 
Goodman et al., 2016). 
  
 
 
 
24h 48h 72h 96h 120h 0h 
1st cycle 2nd cycle 3rd cycle 
 
 
 
Figure 7. Targeting housekeeping functions of the apicoplast leads to a 
delayed death of blood stage parasites after 96h of initial erythrocyte 
invasion. 
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Since the killing of blood stage parasites is delayed, these antibiotics cannot be 
used alone for the treatment of malaria. 
However use of these drugs, shown for azithromycin, against the preceding life 
cycle stage of malaria parasites in the liver (characterised by a single round of 
replication), leads to the release of non-infectious merozoites, hence preventing 
the pathogenic blood stage proliferation (Prudencio et al., 2006, Friesen et al., 
2010). The reason for the difference in the killing kinetics between liver stage and 
blood stage is not clear. Possibly, the immediate effect of antibiotics against liver 
stages could be related to the elevated requirement for housekeeping proteins 
caused by the massive replication in the liver stage (producing tens of thousands 
of progeny). Disruption of apicoplast biogenesis and thus, inhibiting de novo fatty 
acid synthesis would be expected to lead to parasite arrest at the late liver stage. 
Indeed, the pharmacologically induced anti-liver stage effect phenocopies the 
type II fatty acid knockouts  (Yu et al., 2008). 
The essential role of the apicoplast for the survival of blood and liver stages offers 
a great opportunity as drug target for interventions and prophylaxis against 
malaria, including regarding emerging resistance to current first-line treatments 
(Mukherjee and Sadhukhan, 2016). 
Additionally, since liver stage infection depends on fewer parasites than blood 
stage infections, representing a smaller parasite burden and furthermore an 
asymptomatic infection state - this “bottleneck” of the parasite’s life cycle is a 
promising starting point for prophylactic interventions: inducing sterile immunity 
by antigen presentation to the host’s immune system without causing malaria 
symptoms. 
 Naturally acquired immunity against P. falciparum 
malaria 
Residents in endemic malaria areas develop a partial immunity against P. 
falciparum infections (also named ‘semi-immunity’). Immunity that shields against 
severe malaria can be acquired after only a few malaria episodes and is further 
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enhanced after multiple re-infections, preventing also uncomplicated disease 
episodes  (Gupta et al., 1999). However, immunity that limits parasite proliferation 
develops much slower and there is controversy over providing full sterile 
protection does not seem to provide full sterile protection against re-infection (K. 
Marsh, 2006, Tran et al., 2013, Lell et al., 2018). 
 
 Current prevention strategies against malaria 
The best protection against malaria is the prevention of infection. Several 
intervention strategies are currently being used for malaria control. 
1.5.1 Implemented prevention strategies against malaria 
 
Several approaches of malaria prevention have been successfully implemented 
worldwide, resulting in declining numbers of cases and deaths: in the five year 
period from 2010 to 2015, a decrease of 21% of reported cases and 29% of 
deaths was achieved (WHO, 2017). 
First of all, personal protection measures such as insecticide-treated bed nets (in 
2015, 57% of the population living at risk sleeping under ITN) or indoor residual 
spraying for vector control play the main role in preventing malaria: from 2001 to 
2015 69% of cases have been prevented thanks to ITNs (Bhatt et al., 2015). Still, 
in 2015 43% of people living at risk were not protected with either of the options. 
Secondly, fast access to diagnosis, treatment and medical care is important. 
Thirdly, various intermittent preventive treatment (IPT) schemes with anti-malarial 
drugs are being deployed for averting malaria in the most vulnerable population 
groups: pregnant women and children. IPTs have been shown to be effective but 
coverage has to be expanded further (WHO, 2017). 
Probably, the most promising long-lasting way to eliminate malaria is a 
vaccination. This has been demonstrated for other diseases, showcased by the 
success of the smallpox virus vaccine (Henderson, 1987).  
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The first vaccine candidate against P. falciparum malaria,  RTS,S/AS01 is a 
recombinant vaccine consisting of T-cell and B-cell epitopes of the 
circumsporozoite protein of P. falciparum fused to the hepatitis B surface antigen. 
RTS,S has received a positive opinion by the EMEA but is not yet available on 
the market. It will be further studied in a large implementation phase IV trial in 
three sub-Saharan African countries (WHO press release 17.11.2016). The 
vaccine provides limited protection (17% efficacy against infection after 5 years) 
in children 5-17 months old (White et al., 2015).  Although RTS,S shows that a 
malaria vaccine can be developed, further development of other promising 
approaches, e.g. whole-organism vaccine protocols, is needed to attain a safe, 
affordable and perhaps even more potent vaccine. 
 Whole organism vaccinations  
Considerable progress has been made with whole-parasite vaccine protocols. 
These protocols rely on the inoculation of volunteers with either live or attenuated 
parasites, either as sporozoites or as blood stages. For experimental vaccine 
protocols, sporozoites can be inoculated via bites from infected An. stephensi 
mosquitoes or via intramuscular or intravenous injection of aseptic, cryo-
preserved sporozoites isolated from sterilely raised An. stephensi mosquitoes.   
Wildtype or attenuated sporozoites that are able to infect hepatocytes provide 
antigen stimulation of the host’s immune Infections are arrested either during the 
liver stage or during the first intra-erythrocytic cycle, preventing potentially life-
threatening pathogenic blood stage proliferation. These protocols can induce 
sterile immunity against challenge with the same strain but provide only limited 
strain-transcending protection (Meta Roestenberg et al., 2009, Mordmuller et al., 
2017, Walk et al., 2017). 
Regarding the potency of protection, hepatocyte invasion and subsequent 
parasite maturation within the liver cell correlates with robust immunity. Protection 
depends on the priming of CD8+ T-cells producing interferon γ  (W. Weiss, 1988, 
Schofield et al., 1987, Jobe et al., 2007, Friesen et al., 2010). This accounts 
especially regarding long term protection (Nganou-Makamdop et al., 2012b).  
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Figure 8. Overview of whole organism vaccination approaches 
(Matuschewski et al., 2014). Several strategies to attenuate Plasmodium sporozoites 
followed by inoculation induce sterile protection against reinfection with the same strain 
while differences in the parasites’ maturation inside hepatocytes exist. 
First trials using heat-killed sporozoites showed the need of metabolically active 
and invasion competent parasites. The vaccination did not induce long term 
sterile protection (Hafalla et al., 2006, Alger and Harant, 1976). 
This limitation was overcome by the use of radiation, leading to DNA strand 
breaks of sporozoites’ genome (RAS). Heterologous protection was induced by 
immunisation with bites from thousands of radiation attenuated mosquitos 
harbouring the parasite (Hoffman et al., 2002). 
First shown in a murine model by Mueller et al., genetically attenuated parasites 
(GAS) can be used as an effective approach for inducing sterilising immunity. 
They used knock-out lines lacking an essential gene important in early liver stage 
development in P. berghei parasites (uis-3) (Mueller et al., 2005). 
Importantly, administration of chemoprophylaxis during inoculation of live, fully 
infectious sporozoites (CVac) using chloroquine was shown to induce fully 
sterilising immunity in humans (Mordmuller et al., 2017, Meta Roestenberg et al., 
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2009). Prophylaxis with primaquine also resulted in notable, though incomplete, 
protection (Fryauff et al., 1997).  
The simultaneous usage of azithromycin, a macrolide antibiotic, during 
inoculation of sporozoites revealed a protective immunity against reinfection in 
rodents (Friesen et al., 2010).  
1.6.1 Advantages and disadvantages of different whole organism 
vaccination approaches 
There are several aspects which have to be taken into consideration regarding 
whole organism vaccinations. 
To begin with, logistical problems have to be faced. Due to ethical, safety and 
controlling concerns, vaccination using easily accessible infected mosquitos 
would not receive medical approval due to high infection risk in the manufacturing 
process, coinfection with other pathogens, variable infectivity etc. However, it was 
shown that transportable cryopreserved sporozoites are able to induce malaria 
infection, hence can be used for a chemically attenuated parasite vaccine 
(Roestenberg et al., 2013). Yet, since intravenous inoculation of the vaccination 
is followed by better protection against reinfection well trained local medical 
professionals are required to applicate and supervise the immunisation (Parmar 
et al., 2016). This is an important aspect especially in African countries with poor 
medical supply. 
An important limitation of these approaches is that they induce primarily sterile 
protection against the same strain, i.e. homologous immunity. Due to the 
parasite’s huge antigen diversity, this is not a predictor for a sterile protection 
after natural exposure. On the other hand, there have been also reports about 
cross-stage and even cross-species immunity induced by especially pre-
erythrocytic whole organism vaccinations in mice (Douradinha et al., 2008, Butler 
et al., 2011, Inoue et al., 2012). Hence, antigen diversity between different 
parasite strains and variety in prevalence of strains in various regions have to be 
considered for further investigations of a whole parasite vaccination. For 
example, characterisation of the most common parasites in individual regions and 
specific vaccination combinations.  
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There are some disadvantages taking a closer look at the different approaches: 
 A key concern with radiation-attenuated sporozoites involves the aspect of 
safety. When sporozoites are over-irradiated no protection is achieved whereas 
inoculation of under-irradiated sporozoites can result in incomplete arrest during 
the liver stage and thus, life-threatening blood stage infections after vaccination 
(Silvie et al., 2002). Regarding genetically attenuated parasites, similar concerns 
over the manufacturing process were raised. Faulty gene knock out led to clinical 
malaria in subjects after immunisation (Spring et al., 2013). Since manufacturing 
of chemically attenuated parasites does not depend on the genetic stability and 
phenotype of knock-out lines or DNA breaks, there have been no concerns 
regarding production processes.  
Another important aspect is the timepoint of parasite arrest. Especially the late 
liver stage arrest is predominant regarding the induction of protective immunity 
(Nganou-Makamdop and Sauerwein, 2013, Butler et al., 2011). Chemically 
attenuated parasites show this late stage arrest, whereas most of genetically or 
radiation attenuated parasites are stopped earlier in liver stage development: 
Previous research showed that late-attenuated parasites can induce a better 
protection on a per-injected sporozoite basis against challenge than irradiated 
sporozoites (Friesen and Matuschewski, 2011). 
However, as shown in Figure 8, injection of chloroquine attenuated parasites is 
followed by maturation of the parasite within the liver and even erythrocyte 
invasion, hence can cause a mild malaria infection. In contrast, certain 
approaches using drug cover of parasites with antibiotics, e.g. azithromycin, lead 
to a late liver stage arrest, hence parasites are able to undergo full liver stage 
development and can even emerge from the liver as merozoites but are unable 
to invade erythrocytes and do not cause malaria symptoms (Matuschewski et al., 
2014).  
Additionally, the immunisation approach using chloroquine shows less protection 
than attenuation with azithromycin in mice. This might be due to modulation of 
the immune system by blood stage parasites and presents one more argument 
in favour of late liver stage arrest (Friesen and Matuschewski, 2011). Apart from 
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this, although chloroquine is a well-known anti-malarial drug, there is one main 
disadvantage: resistance especially in African countries (Price et al., 2014). 
Whereas, there are rarely studies concerning resistance of Plasmodium parasites 
to antibiotics like clindamycin resistance in the Amazonas region or induced in 
vitro resistance to azithromycin (Dharia et al., 2010, Sidhu et al., 2007). This has 
to be taken into account considering individual vaccination combinations for 
specific regions. 
In this study, I concentrated on the new macrolide antibiotic solithromycin and its 
potential in a whole organism vaccination approach using chemically attenuated 
parasites. 
1.6.2 Characterisation of solithromycin  
 
Solithromycin is a new fluoroketolid antibiotic, a next-generation macrolide. 
Ketolids are derivatives of the macrolide erythromycin supplemented with a 
ketone group which enables them to bind and inhibit at two sides of the bacterial 
ribosome’s 50s subunit, hence inhibit protein translation even more effective. This 
additional binding side leads to a broader efficacy (Fernandes et al., 2016). 
To solithromycin, the first fluoroketolid, fluorine is added. This results in a third 
binding site at prokaryotic ribosomes, hence a higher affinity to ribosomes as well 
as a potency to act efficiently against macrolide and even ketolide resistant 
bacteria (Llano-Sotelo et al., 2010, Fernandes et al., 2016). In comparison to its 
predecessor, the well-known ketolide telithromycin, solithromycin does not 
possess a pyridine sidechain which is known to inhibit nicotinic acetylcholine 
receptors entailing severe adverse effects like visual disturbance or liver toxicity 
(Fernandes et al., 2016). 
The compound is to date in phase 3 clinical development for treatment of 
community acquired bacterial pneumonia. Previous studies showed a safe use in 
patients including children and pregnant women and people with liver impairment 
(Barrera et al., 2016, Fernandes et al., 2016, Keelan et al., 2016, Jamieson et al., 
2015). However, it was not yet approved by the FDA, which recently expressed 
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concerns about the lack of investigations and data regarding a possible liver 
toxicity of the compound (Abdulla, 2016). 
Regarding antimalarial potential, solithromycin induces delayed death in both, P. 
falciparum and P. berghei blood stages. Moreover, it is more potent than 
azithromycin against multidrug resistant, including azithromycin resistant, lab 
strains of P. falciparum in vitro and shows a higher antimalarial activity against P. 
berghei in vivo compared to azithromycin (Wittlin et al., 2012). Furthermore, 
higher intracellular concentrations than with other macrolides have been 
achieved with this compound (Lemaire et al., 2009). Additionally, malnutrition, 
which is common in African countries, showed no effect on its bioavailability (Still 
et al., 2011).  
 
 Usage of the Hepatitis B virus’ PreS surface protein to 
gain liver specific delivery 
The PreS protein is well known from the hepatitis B virus (HBV). 
The HBV is a highly selective hepatotropic virus. It expresses a hepatitis B 
surface antigen (HbsAg) consisting of different proteins. The large surface 
antigen consists of the preS1, preS2 and S domain. Consisting of solely the 
preS2 and S domain, it is called middle surface antigen. Consequently, S equals 
the small surface antigen (Stibbe and Gerlich, 1983). 
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Figure 9. Structure of the hepatitis B virus (Gerlich, 2013). Note the different 
surface proteins. LHBs= large hepatitis B surface protein, MHBs= middle hepatitis B 
surface protein, SHBs= small hepatitis B surface protein, are collectively the hepatitis B 
surface antigen. 
The PreS1 domain of the large surface protein is the virus’ key for entering the 
liver by binding to the sodium taurocholate cotransporting polypeptide (NTCP), a 
transmembrane transporter on the hepatocyte surface (Yan et al., 2012, Meier et 
al., 2013). 
1.7.1 Physiological function of the NTCP 
 
Hepatocytes physiologically express a sodium taurocholate cotransporting 
polypeptide on their basolateral membrane for reuptake of conjugated and 
unconjugated bile acids from the portal vein within the enterohepatic circulation 
(Mita et al., 2006). 
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Figure 10. The NTCP of hepatocytes, its physiological function and 
targeting structures (Yuen and Lai, 2015). The sodium taurocholate 
cotransporting polypeptide is expressed on hepatocytes for bile acid reuptake but also 
serves as the functional receptor of the hepatitis B virus and iatrogenic interventions. 
1.7.2 Therapeutic approaches  
 
The identification of NTCP as the functional receptor for the hepatitis B virus 
opened several novel approaches to inhibit the virus’ entry of the liver. Novel 
interventions include preventing the virus’ access to the liver by blocking the 
receptor e.g. with ciclosporin or Myrcludex B, which is a derivative of the large 
surface protein of HBV (Yuen and Lai, 2015, Petersen et al., 2008, Watashi et 
al., 2014a). 
This knowledge about the entry mechanism of HBV was also used by Zhang et 
al. to create a liver specific transportation. The conjugation of a lipopeptide 
derived from the PreS1 surface antigen and pegylated liposomes resulted in 
precise transport of conjugated drugs to hepatocytes. This approach showed a 
higher efficacy of these drugs within the liver parenchyma (Zhang et al., 2015). 
Lately, an approach using a conjugation of lipid modificated nanoparticles and 
myristoylated PreS-peptide also showed a specific binding to NTCP as well as 
initialization of molecules into hepatocytes (Witzigmann et al., 2019). 
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A specific transportation to the liver of drugs is an interesting approach for the 
usage of antibiotics in whole organism vaccinations. Peptide-conjugated drugs 
could be used as an inoculation additive and so be applied at the same time 
parasites are injected into the patient. Giving a single shot of this combination 
could result in the reduction of drug dose as well as reduction of systemic side 
effects of the antibiotic applied and an even stronger efficiency as well as 
improved patients’ compliance. 
Additionally, the usage of PreS1 for liver specific transportation could be used for 
already established anti-malarial drug therapies. For example, primaquine which 
cannot be applied as a treatment regarding special patient groups. 
 Primaquine and its adverse side effects 
Primaquine is indispensable in malaria treatment. It is the only drug capable of 
eliminating liver hypnozoites of P. vivax and P. ovale, available since the 1950s 
(John et al., 2012). Additionally, P. falciparum’s sexual blood stages 
(gametocytes) are sensitive to the drug, which results in a lower count of 
gametocytes, hence a reduced transmission of the parasite (Graves PM, 2014). 
However, there are significant adverse side effects associated with this drug. It 
can induce haemolysis in people suffering from Glucose-6-phosphate-
dehydrogenase deficiency (Clyde D.F., 1981). This is a big issue in sub-Saharan 
Africa because G6PDH deficiency represents a natural protection against severe 
Malaria and therefore is widespread in Malaria endemic areas (Mbanefo et al., 
2017). 
Primaquine is also contraindicated in pregnancy (Fernando et al., 2011). 
Pregnant women represent a special risk group regarding malaria infection: the 
women’s immune system is complex modulated and therefore more prone to 
malaria infections (Szekeres-Bartho and Wegmann, 1996, Mor and Cardenas, 
2010). Additionally, a special surface antigen is expressed in infected red blood 
cells (VARS2CSA) which binds to receptors expressed on the placental surface 
(chondroitin sulphate A). This sequestration can end in placental insufficiency 
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(Takem and D'Alessandro, 2013, Ismail et al., 2000). Women also suffer from 
undetected P. vivax rebounds during pregnancy (Yanow et al., 2016). 
Because of these severe side effects, it would be preferable if primaquine could 
be delivered specifically to hepatocytes only.  
 
 Aim of the study 
Despite being a treatable and preventable disease, malaria still has a huge 
impact on global health. There are several successfully implemented strategies 
to contain this disease and help people living at risk of infection. Additionally, as 
described above, the first anti-malarial vaccine candidate is on its way to approval 
but does not provide the efficacy wished for. 
There still is the need to develop a safe, affordable and effective vaccine and 
eventually eliminate this disease worldwide.  
The first part of this study pays attention to an antibiotic-based inhibition of the 
malaria parasite. I focused on the new antibiotic solithromycin and if it is a suitable 
candidate to attenuated malaria parasites regarding the usage in a whole 
organism vaccination protocol.  
At a first step, solithromycin’s mode of action on P. falciparum blood stage 
parasites was tested to identify its attenuation effect and target within the 
parasite. Secondly, solithromycin treated parasites were tested in a mouse model 
to verify the capability of parasite development in hepatocytes, hence immune 
system stimulation. However, the injection of merosomes which emerged from 
hepatocytes into mice was not followed by parasitemia, thus these noninfectious 
merosomes were not able to cause malaria symptoms. 
As a second part, I focused on the potency of PreS1 conjugated drugs regarding 
liver specific delivery. In this study, I examined the effect of PreS1-conjugated 
primaquine, an anti-malarial drug.  
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PreS1 is a component of the hepatitis B virus’ large surface antigen, crucial for 
hepatocyte invasion. This hepatotropic characteristics can be transferred to a 
drug by conjugation, thus reducing the specific systemic adverse side effects and 
dose. In this case, the usage of this conjugation is interesting regarding an 
application within a whole organism vaccination using antibiotics. As an injectable 
conjugation, it could be applied simultaneously with the parasites even in one 
single syringe. I studied the effect of PreS1-conjugated primaquine, whose effect 
on Plasmodium parasites are well-studied. The conjugation was tested on P. 
berghei liver stage parasites developed in hNTCP HuH7 cells. 
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2 Materials and Methods 
 Materials 
Disposables 
1.2µm Syringe filter Sartorius 
8 well chamber slides Thermo scientific 
Aluminium foil Roth 
Coverslips Marienfeld 
Cryovials Greiner bio-one 
Culture flasks T25 and T75 Greiner bio-one  
Gloves Nitrile powder free Abena 
Insulin syringes BD Discardit II 
Microscope slide Thermo Scientific, ground edges, 
frosted ends 
Needles (27G, 23G, 30G) BD Microlance 
Pipette tips Greiner bio-one 
Sterile filter  Milipore, 0.22 µm, steritop 
Stripettes Sarstedt  
Tubes 15ml, 50ml Falcon, Sarstedt, greiner bio one 
Tubes 1ml, 2ml  Eppendorf 
 
Chemicals 
0+ erythrocytes Zentrum für Klinische 
Transfusionsmedizin, University 
Tübingen 
Albumax II Invitrogen 
Anti-anti Life technologies 
Azithromycin Pfizer 
Bovine Serum Albumin Roth 
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Disinfection Descosept AF 
DMEM medium Life technologies 
DMSO gruessing 
E64 Sigma Aldrich 
FCS Us certified heat inactivated Life technologies 
Gentamicin Invitrogen 
Giemsa Merck 
HBSS Life technologies 
Human AB+ serum Zentrum für Klinische 
Transfusionsmedizin, University 
Tübingen 
Hypoxanthine  ccpro 
Immersion oil ImmersolTM W Zeiss 
IPP Sigma Aldrich 
Macs columns Miltenyi biotec 
Methanol Sigma- Aldrich  
Nailpolish Essence 
Penicillin/streptomycin Life technologies 
PFA Roth 
Phosphate buffered Saline Life technologies 
PreS1-Primaquine AG Urban, University of Heidelberg 
Primaquine Mpbio 
RPMI 1640 Thermofisher Scientific 
Solithromycin Cempra 
Sorbitol Fluka Biochemika  
Trypsin EDTA Life technologies 
 
Equipment  
Climate chamber Mytron 
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Centrifuge Hettich Rotanta 
Centrifuge 5415R eppendorf 
CO2  incubator Thermo scientific HERAcell 150i 
Freezer -20°C, Fridge 5°C Liebherr 
Freezer -80°C Heraus, thermo scientific 
Haemocytometer Labotec 
Light microscope Nikon Eclipse E200 
Megafuge R 1.0 Heraus 
Microscope Axioskop 40 Zeiss 
Mosquito cages  BioQuip Products Inc 
Pipette dispenser Integra pipette boy 
Pipettes Eppendorf, Abimed 
Scale  Mettler Toledo 
Stereo microscope Stemi 2000C Zeiss 
Water bath Bachofer 
Work bench Hera safe Thermo fisher 
Zeiss Axio Observer Z.1  AG Schenke-Layland Dept.of 
Women's Health Research Institute 
for Women's Health, Tübingen 
 
 
Antibodies 
Alexa Fluor 488 (goat anti-mouse) Invitrogen 
Alexa Fluor 546 (goat anti-mouse) Invitrogen 
Alexa Fluor 546 (goat anti rabbit) Invitrogen 
Anti PbACP serum eurogentec 
Anti PbCSP Hybridoma supernatant 
Anti PbHSP70 Hybridoma supernatant 
Hoechst 33342 Invitrogen 
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Biologicals 
Anopheles stephensi Max Plank Institute for Infection 
Biology, Berlin 
Huh7 hepatoma cell line AG Bartenschlager, University of 
Heidelberg 
HuH7hNTCP cell line AG Urban, Centre for Infectious 
Diseases, Molecular Virology, 
Heidelberg 
NMRI mice Janvier, France 
 
Computer softwares 
Fiji ImageJ 1.51e 
Prism 5.0 Graph Pad  
Endnote X7.5 Thomson Reuter 
 
 Methods of Plasmodium falciparum 3D7 blood stage 
parasite culture 
Plasmodium falciparum 3D7 parasites were cultured in vitro modified after Trager 
and Jensen (Trager and Jensen, 1976). 
2.2.1 Blood culture conditions of P. falciparum 3D7 parasites 
Parasites were cultured in T75 or T25 culture flasks. The complete medium 
contained RPMI 1640 (supplemented with L-Glutamine and 25nM HEPES), 10% 
Albumax II, 2% Human AB+ serum, 1% Hypoxanthine and 0.05% Gentamicin; 
0+ erythrocytes at a haematocrit of 5% were supplemented, cultures were kept 
in an incubator at 37°C, 5% CO2 and 5% O2.  
For observing growth and parasitaemia of the culture, thin blood smears were 
prepared by using circa 2 µl of the culture’s erythrocytes and spreading them 
equally on a microscope slide.  
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Subsequently, the smear was fixed for 1 minute in 100% methanol and stained 
15 minutes in 5-10% Giemsa solution. The slides were examined by light 
microscopy using a 100x objective and immersion oil. 
Parasitaemia was kept at around 1-2% by changing medium and blood regularly.  
2.2.2 In vitro drug assay 
To test the potency of the drug at time point zero, particularly with regard to a 
possible inhibition of erythrocyte invasion, merozoites were isolated modified 
after Boyle et al. (Boyle et al., 2010b). 
Untreated Plasmodium falciparum 3D7 blood cultures show a mixed picture of 
parasite’s stages. To synchronise the parasites’ development, the following 
procedure was undertaken: 
Table 1. Experimental setup of P. falciparum 3D7 blood culture 
synchronisation. 
 
The released merozoites were given in incomplete medium (without Albumax and 
serum), a suitable concentration of compounds and erythrocytes for 30 minutes 
for invasion of red blood cells. After that period, serum and Albumax was added. 
 
Day of  
synchronization 
Treatment Effect 
0  Sorbitol  (Lambros and 
Vanderberg, 1979) 
Only ring stages remain 
1 Magnetic separation 
(Ribaut et al., 2008) 
Only late trophozoites remain 
2 Heparin 250µg/ml (Boyle 
et al., 2010a) 
No further invasion of erythrocytes 
 
3 Magnetic separation Only late trophozoites remain 
4 Heparin No further invasion of erythrocytes 
7 Incubation with E64(5-8h) No rupturing of schizonts 
7  Filter through 1.2µm filter Mechanical release of merozoites 
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Solithromycin treatment assay 
In order to test the efficacy of solithromycin, the established IC50 and IC99 for P. 
falciparum blood stage parasites were tested (Wittlin et al., 2012). 
Synchronised merozoites were equally divided into three T25 flasks and exposed 
to 3 nM, 10 nM solithromycin or 0.001% DMSO as control with a starting 
parasitaemia determined at 0.5% with a haematocrit of 1%. Development of the 
culture was observed over 96 hours by preparing thin blood smears. 
Apicoplast free 3D7 drug assay 
Depletion of the apicoplast of P. falciparum 3D7 was implemented by following 
the procedure by Yeh and DeRisi (Yeh and DeRisi, 2011). Briefly, parasites were 
treated with clindamycin in order to target the apicoplast. These treated parasites 
were subsequently supplemented with 200 µM IPP at several time points after 
the first cycle of multiplication in erythrocytes. This procedure was undertaken to 
rescue the parasite but dispose the prokaryotic organelle. Parasites were further 
cultured in vitro while changing the medium supplemented with IPP every two 
days. IPP concentration was reduced after adaption of the parasites in steps of 
50 µM. Parasites used for the presented experiments were adapted to a 
concentration of 100 µM IPP. 
Synchronised (see above) 3D7 and 3D7 apicoplast free (ap-) falciparum ring 
stages with a start parasitaemia of 0.5% and a haematocrit of 1% were subjected 
to the following experimental setup: 
Table 2. Experimental setup of P. falciparum apicoplast free assay. 
 Apicoplast free 3D7 3D7 
Control 0.001 % DMSO + 100 µM IPP 0.001 % DMSO 
Solithromycin 10 nM solithromycin + 100 µM 
IPP 
10 nM solithromycin 
Clindamycin 50 nM clindamycin + 100 µM IPP 50 nM clindamycin 
 
The culture was observed over 120 h via thin blood smears.  
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 Methods of Plasmodium berghei ANKA parasites 
All experiments were undertaken with P. berghei ANKA cl15cy1 at the 
Parasitology Unit, Ann-Kristin Müller lab, Centre for Infectious Diseases, 
Heidelberg. 
2.3.1 Imitation of the parasite’s life cycle  
 
For Plasmodium berghei and this experimental setup, it is necessary to imitate 
the life cycle of the parasite. 
Eggs of female Anopheles stephensi mosquitos were collected 4 days after a 
blood meal (see below) and washed with 70% ethanol and 0.1% salt solution. 
They were bred in trays containing 0.1% salt solution at 28°C and 80% humidity. 
Two or three days after, the larvae were again split and fed with cat food. Within 
one week they developed into pupae. Two days later the hatched mosquitos were 
transferred into cages and fed via cotton pads soaked with 0.1% salt solution or 
10% sucrose solution. 
Malaria naïve female NMRI mice were infected with P. berghei ANKA positive 
mouse blood samples by intraperitoneal injection on two following days. Four 
days later, when exflagellation of male gametocytes in a thin blood smear could 
be observed, mice were anaesthetised with 70 - 100 µl Ketamine/Xylazine 
respectively. The mice were laid on a mosquito cage with 4 days old Anopheles 
stephensi for a 15 minutes blood meal for infection with P. berghei ANKA. 
Infected mosquitos were kept in an incubator at 21°C and 80% humidity. 
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Figure 11. Anopheles stephensi mosquito cages in incubator 
Estimation of infection rate  
After 10 days, mosquito infection was assessed by detecting the occurrence and 
number of oocysts in the midguts of Anopheles mosquitos. 
Up to 5 mosquitoes were anaesthetised on ice and midguts were dissected in 
RPMI medium containing 3% BSA. Afterwards, the midguts were analysed by 
preparing them on a glass slide under a coverslip. Examination was performed 
by light microscopy using a 40x objective and phase contrast. 
Hence, by observing the total number of infected midguts, infection intensity was 
estimated. 
 
Isolation of sporozoites  
Mosquitos were dissected 17 to 23 days after infection. To extract sporozoites 
out of the salivary gland, Anopheles stephensi mosquitos were anaesthetised on 
ice and dissected in RMPI supplemented 3% BSA under a stereomicroscope 
using insulin syringes and needles. Afterwards, salivary glands were 
homogenised using an EPPI-Pistill.  
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Figure 12. Dissection of Anopheles stephensi mosquitos 
The homogenised salivary glands were centrifuged for 3 minutes / 1000 rpm at 
4°C. The supernatant containing sporozoites was transferred into a new 
Eppendorf tube, the pellet resuspended in RPMI/ 3% BSA and again centrifuged. 
The new supernatant was transferred into the tube as well. To calculate the 
number of sporozoites, the suspension was diluted, placed into a hemocytometer 
and sporozoites were counted using light microscopy and phase contrast. The 
following formula was used to calculate the total number of extracted sporozoites: 
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓
𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠
𝑚𝑚2
×  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ×  104  =
𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠
𝑚𝑙
 
     
2.3.2 Culture conditions of HuH7 cell line and hNTCP Huh7 cell line 
Culturing of hepatocytes was performed under sterile conditions. 
The Huh7 required a culture medium containing DMEM Medium (supplemented 
with D-Glucose, L- Glutamine and Pyruvate), 10% FCS + 1% Anti – anti 100x.  
The cell line hNTCP HuH7 was essential for the PreS1-conjugated drug assay. 
The PreS1 domain physiologically binds to the polypeptide hNTCP (see section 
1.7) The hNTCP HuH7 cell line expresses this binding site, hence the PreS1 
conjugated drug can be delivered into the hepatocyte. The cells were cultured in 
a medium containing DMEM Medium (also supplemented with D-glucose, L- 
glutamine and pyruvate), 10% FCS + 1% penicillin/streptomycin. 
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Both cultures were maintained in T25 or T75 culture flasks, in an incubator at 
37°C and 5% O2 and split regularly: cells were washed with prewarmed HBSS 
(without CaCl2 and MgCl2), incubated 3 minutes with prewarmed 0,25% trypsin-
EDTA to solve them from the flask. Trypsinization was stopped by adding 10ml 
of cell culture medium and then centrifuged for 3 minutes / 1000 rpm. Up to 1 ml 
of the pellet was resuspended in culture medium and transferred into a new flask. 
2.3.3 In vitro drug assay 
Drug assays were performed under sterile conditions. 
 
 
Infection of hepatocytes 
One day prior to sporozoite infection, hepatocytes were seeded into 8-well 
chamber slides. 
COMPOUNDS 
P. berghei sporozoites 
immunofluorescence assays / 
merosome harvesting 
Hepatocytes 
(hNTCP) HuH7 
 
Figure 13. Experimental set-up: Effect of compounds on pre-erythrocytic 
development.  After dissection, P. berghei sporozoites and compounds were added 
to (hNTCP) HuH7 and developed until stopped at different time points. 
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To achieve a total number of 25 000 cells/ well, cells were prepared as described 
above (see section 2.3.2). After centrifugation, an aliquot of the pellet was diluted 
1:5 in Trypan blue, and counted by using a hemocytometer (formula as described 
above (see section 2.3.2 ). Afterwards, the cell suspension was diluted to achieve 
an overall number of 25 000 cells in 400 µl culture medium per well respectively. 
The chamber slides were incubated overnight at 37°C and 5% O2. The following 
day sporozoites were extracted as described above (see section 2.3.1) and, 
depending on the experimental setup, 10 000 or 25 000 sporozoites, diluted in 
100 µl RPMI, were pipetted in each well and incubated for 90 minutes at 37°C for 
sporozoite invasion of hepatocytes. 
Drug treatment 
After 90 minutes of incubation, 400 µL of supernatant containing sporozoites that 
failed to invade was removed from the wells. Subsequently, 400 µl of culture 
medium containing the needed concentration of compounds was replaced. 
Solithromycin assay:  
• solithromycin (solved in DMSO) 10 µM 
• solithromycin (solved in DMSO) 1 µM 
• azithromycin (solved in distilled H2O) 1 µM 
• control: 0.01% DMSO 
Every compound was further diluted in HuH7 cell culture medium. 
PreS1- conjugated drugs assay: 
• primaquine (solved in PBS) 10 µM 
• PreS1-primaquine (solved in DMSO) 10 µM 
• control: 0.01 % DMSO 
Every compound was further diluted in hNTCP HuH7 cell culture medium. 
After incubation of 48 or 65 hours, slides were fixed for 10 minutes with ice-cold 
methanol, afterwards blocked with 10% FCS/PBS for 30 minutes at 37°C or 
overnight at 4°C. 
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Immunofluorescence staining 
Antibodies were diluted in 10% FCS/PBS, washing steps were performed with 
1% FCS/PBS. 
To visualize the apicoplast of liver stage parasites, 100 µl of an anti-PbACP rabbit 
antiserum 1:1000 was applied and incubated for 1 hour at 37°C. The wells were 
then washed five times. Subsequently, 100 µl of a secondary antibody anti-rabbit 
Alexa Fluor 546 1:300 was applied and incubated for 45 minutes at 37°C. 
After three washing steps, the wells were again blocked with 10% FCS/PBS for 
15 minutes at 37°C. 
After three times of washing, 100 µl of an anti- HSP70 mouse antibody 1:100 was 
applied and incubated for 30 minutes at 37°C. This was again followed by three 
times of washing and incubation with 100 µl of a secondary anti-mouse Alexa 
Fluor 488 antibody 1:300 for 20 minutes at 37°C. 
Finally, DNA was stained by adding 100 µl Hoechst 33342 1:1000 to the previous 
antibody. Ten minutes later three washing steps followed. Slides were then 
mounted with 50% glycerol in PBS and coverslips fixed with nail polish.  
Parasite numbers in each well were counted after 48 or 65 hours of development 
via epifluorescence microscopy. Sizes measured with the Fiji package in Image 
J. 
Invasion assay 
This assay was set up to test if solithromycin had an impact on the capability of 
P. berghei sporozoites to invade hepatocytes. 
HuH7 cells were plated in chamber slides as described above (see section 2.3.2). 
In comparison to the treatment assay, the extracted sporozoites were incubated 
for 30 minutes in either 10 µM solithromycin/RPMI or 0.01% DMSO/RPMI 
(control) on ice. Afterwards 10 000 treated sporozoites were added to each well. 
After 90 minutes of invasion, slides were fixed with 4% PFA/PBS for 10 – 20 
minutes at room temperature and blocked with 10% FCS/PBS for 30 minutes at 
room temperature or overnight at 4°C. 
 36 
 
Subsequently, immunofluorescence staining was performed to show the ratio of 
the number of sporozoites that successfully invaded vs. the number of 
sporozoites that failed to invade. 
To visualize the sporozoites which were not able to invade hepatocytes, an anti-
PbCSP mouse antibody 1:300 was added to each well and incubated for 1 hour 
at 37°C. After four times of washing, a secondary goat anti-mouse Alexa Fluor 
546 antibody 1:300 was added to each well and incubated for 1 hour at 37°C as 
well and afterwards washed four times. A fixing step with ice-cold methanol for 
10 minutes at room temperature followed by 30 minutes of blocking with 10% 
FCS/PBS was performed. As a result of this treatment, the antibodies can 
penetrate into the cells and stain intra-hepatocytic sporozoites. Consequently, to 
stain all sporozoites, the anti-PbCSP mouse antibody 1:300 was again added to 
each well but this time, a goat anti-mouse Alexa Fluor 488 1:300 followed, and 
was also incubated for 1 hour at 37°C. 
The slides were mounted and covered as described above (see section 2.3.3). 
The number of sporozoites was counted via immunofluorescence microscopy. 
The following formula for the calculation of the proportion of successfully invaded 
sporozoites was used: 
 
(𝑡𝑜𝑡𝑎𝑙  𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠 − 𝑛𝑜𝑡 𝑖𝑛𝑣𝑎𝑑𝑒𝑑 𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠)
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠
 𝑥 100 
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Figure 14. Invaded and failed to invaded P. berghei sporozoite.  Due to the 
special order of staining processes, sporozoites which did not invade hepatocytes 
appear red while all sporozoites (invaded and not invaded) appear green. Scale bar 
indicates 5µm. 
 In vivo experiments with P.berghei ANKA 
All in vivo experiments were approved by the relevant authority 
(Regierungspräsidium Karlsruhe no. G260/12), performed under European 
regulations and supervision by an appropriated person. 
NMRI mice were kept in the animal shelter of the University of Heidelberg. 
2.4.1 Culturing of P. berghei liver stage merosomes 
 
Merosome formation requires an incubation time of 70-75 hours of P. berghei 
liver stages. Therefore 8 well- chamber slides were seeded with HuH7 cells, each 
well was infected with 50 000 sporozoites and treated with either 10 µM 
solithromycin or 0.01% DMSO as described above (see section 2.3.3.). The 
slides were incubated for 72 hours at 37°C and cell culture medium containing 
compound or control was changed daily. 
72 hours after infection, merosomes appeared in the supernatant of the wells. 
Hence, the supernatant was carefully pipetted up and down and transferred in an 
Eppendorf tube, which was centrifuged for 5 minutes / 1200 rpm at room 
temperature. 
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Figure 15. Experimental setup: effect of solithromycin on merosome infectivity. 
Hepatocytes were infected with P. berghei sporozoites and simultaneously treated with 
solithromycin. Merosomes were harvested 72 hours after infection and injected into NMRI 
mice. Parasitaemia was controlled via thin blood smear. 
 
 After centrifugation, the supernatant was taken off and 400 µl of culture medium 
was applied to wash out the drug. The tubes were centrifuged again and the 
supernatant was taken off. Afterwards, the merosome containing pellets were 
suspended and merosomes examined and counted using light microscopy and 
phase contrast with a hemocytometer. The total number of merosomes was 
calculated and diluted for injection. 
2.4.2 Infection of NMRI mice with P. berghei liver stage merosomes 
 
A suitable amount of merosomes was injected i.v. into the tail vein of NMRI mice 
using an insulin syringe (U100, 12,7 mm, 30G). After 3 days of infection, thin 
blood smears were performed daily to detect parasitaemia. 
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 Statistics 
Graph Pad Prism was used for statistical analyses.  
Gaussian distribution was estimated applying D’Agostino and Pearson omnibus 
normality test plus Kolmogorov-Smirnov test. 
P values were calculated using the student’s t-test if Gaussian distribution was 
confirmed or Mann-Whitney test if not. Data that are normally distributed were 
summarized using descriptive statistics, e.g., using the mean (SD). Non-
parametric data were summarized using the median and the interquartile range 
or range. 
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3 Results 
 Effect of solithromycin on P. falciparum 3D7 blood 
stage parasites 
Initially, I was keen to verify the effect of solithromycin on P. falciparum blood 
stage parasites. Special focus was on whether the compound uses the apicoplast 
as a target or not. Since it is known that inhibiting the apicoplast’s inheritance 
results in delayed death of blood stage parasites, I focused especially on the 
parasites’ development over 96 hours, hence more than one multiplication cycle. 
 I tested the effect of two published concentrations (IC50 of 3 nM and IC99 of 10 
nM) on P. falciparum 3D7 blood stage proliferation (Wittlin et al., 2012).  I applied 
1 µM of azithromycin as a reference for the ‘delayed death’ phenotype induced 
by interfering with prokaryotic protein translation in the apicoplast (Friesen et al., 
2010). 
3.1.1 Effect of solithromycin on erythrocyte invasion of P. falciparum 
3D7 blood stage merozoites 
To investigate whether solithromycin has an influence on merozoite invasion of 
erythrocytes it is necessary to test the compound at time point zero after 
merozoites emerge from mature schizonts but before invasion of erythrocytes. 
Therefore, P. falciparum merozoites were isolated as described above (see 
section 2.2.2) and exposed to the compound during invasion, i.e., when freshly 
isolated merozoites were added to uninfected erythrocytes suspended in culture 
medium. 
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Figure 16. Exposure to solithromycin did not affect the initial merozoite 
invasion of erythrocytes but shows delayed death of parasites. P. falciparum 
merozoites were exposed to different concentrations of solithromycin (sol 3 = 3 nM 
solithromycin; sol 10 = 10 nM solithromycin; co= 0.001% DMSO) and observed over 96h. 
Figure 16 depicts the growth of P. falciparum blood stage parasites after 
exposure of merozoites to solithromycin; a concentration of 3 nM corresponds to 
the IC50, 10 nM the IC99. The compound did not inhibit merozoite invasion of 
erythrocytes. Solithromycin exposed cultures grew at the same rate as the 
untreated control culture over the first two cycles of exposure. However, I 
observed the delayed death of solithromycin exposed cultures after 96 hours of 
infection, which suggested a defect of apicoplast inheritance. 
3.1.2 Effect of solithromycin on P. falciparum blood stage parasites 
lacking the apicoplast 
To test this hypothesis, I tested the compound on P. falciparum blood stages 
lacking the apicoplast. Parasites were treated with clindamycin and 
supplemented with IPP to achieve removal of the apicoplast while keeping the 
parasite alive. IPP is the only essential metabolic product of the apicoplast in 
Plasmodium blood stages (see section 1.3.1). Apicoplast-negative parasites 
were designated as ap-. Synchronised P. falciparum 3D7 and P. falciparum 3D7 
ap- ring stages were treated as described above (see section 2.2.2) with either 
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10 µM solithromycin, 50 nM clindamycin as positive or 0.001% DMSO as 
negative control. Parasitaemia was monitored via thin blood smears over 120 
hours. 
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Figure 17. Growth of apicoplast free P. falciparum blood stage parasites 
was not affected by solithromycin treatment.  Synchronised ring stages were 
incubated with compounds and observed over 120h.  A) Control 3D7 parasites turned 
into the third cycle of development after 72h while treated parasites stayed in the second 
cycle. (= delayed death). Apicoplast free 3D7 parasites supplemented with IPP got into 
their third cycle after 120h, even parasites under drug treatment. B) Microscopy pictures 
of developed parasites. Solithromycin and clindamycin treated P. falciparum 3D7 with 
apicoplast did not develop further than two cycles of schizogony, stayed in schizont stage 
and died eventually. Whereas the parasites lacking the apicoplast but supplemented with 
100 µM IPP continued their development.  Means of two independent experiments. 
As shown in Figure 17, ap- parasite growth was not affected by treatment with 
solithromycin or clindamycin. Solithromycin and clindamycin treated parasites 
from the lab strain 3D7 showed the typical delayed death: treated parasites were 
not able to develop further than a second cycle of erythrocyte invasion.  
Compared to the wildtype P. falciparum lab strain 3D7 ap- parasites were slightly 
delayed in their development. 
 Effect of solithromycin on P. berghei Huh7 liver stage 
parasites 
After receiving the results of solithromycin’s effect in blood stage parasites, 
suspecting that the compound targets the apicoplast, I continued my experiments 
focusing on the liver stage of Plasmodium parasites.  
To find out if solithromycin could be a candidate drug for a chemo attenuated 
whole parasite vaccine protocol, its potency and detailed mode of action against 
liver stages needs to be demonstrated. To start this analysis, I held on to the life 
cycle of the parasite. 
 I started this analysis by treating P. berghei ANKA sporozoites with the 
compound to detect a possible effect (see section 2.3.3). As a second step, I 
infected HuH7 hepatocytes with P. berghei ANKA sporozoites as described in 
material and methods (see section 2.3.3). Developing liver stage parasites were 
treated with either 1 µM or 10 µM solithromycin, the corresponding concentration 
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of DMSO served as control. I used 1µM azithromycin as a positive control due to 
its known effect described above (see section 1.3.2). 
3.2.1 Effect of solithromycin on invasion rates of P. berghei 
sporozoites in hepatocytes  
 
To be a usable candidate, solithromycin should not inhibit the invasion capability 
of sporozoites. Initially, I tested the potential inhibitory potency of solithromycin 
on hepatocyte invasion. P. berghei sporozoites were incubated with either 10 µM 
solithromycin or 0.01% DMSO for 1 hour prior to invasion of HuH7 hepatocytes. 
Sporozoites, which were unable to invade hepatocytes were stained with an anti-
PbCSP antibody and Alexa fluor 546 as a secondary antibody, before 
visualisation via fluorescence microscopy. Afterwards, all sporozoites regardless 
of invasion status were stained by the anti-PbCSP antibody and Alexa fluor 488 
as secondary antibody, again before fluorescence microscopy. 
Figure 18. Solithromycin did not affect the capacity of P. berghei 
sporozoites to invade hepatocytes.  Sporozoites were incubated with 10 µM 
solithromycin or 0.01% DMSO as control and afterwards invaded hepatocytes for 90 
minutes. A) There was no significant difference in the number of sporozoites that 
successfully invaded or not between control and solithromycin. B) The invasion rate of 
treated and untreated sporozoites showed no significant difference. Data from three 
independent experiments. ns= non-significant, Mann-Whitney U test. Error bars indicate 
median and range. 
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Figure 18 illustrates the overall number of sporozoites that did or did not 
successfully invade after 90 minutes. As shown, the incubation with solithromycin 
prior to hepatocyte invasion did not affect the number of successfully invaded 
parasites. 
Following this observation, I used an extended experimental setup to investigate 
whether intrahepatocytic parasite numbers are affected by solithromycin 
treatment at 65 hours post invasion.  
 
Figure 19. Incubation of sporozoites with solithromycin prior to invasion 
did not block the development of liver stage parasites after 65 hours. Treated 
sporozoites were counted after 65h of development. CO = 0.01% DMSO (n= 6); SOL = 
10 µM solithromycin (n= 10). Data represent two independent experiments. ns= non-
significant, Mann-Whitney U test. Whiskers indicate median and range. 
As shown in Figure 19, the number of P. berghei liver stages, which developed 
from with sporozoites that were pre-incubated with solithromycin, was not 
significantly different from the control group. 
3.2.2. Analysis of parasite development in HuH7 hepatocytes 
P. berghei liver stage parasites were cultured and treated with the given 
compounds. Cultures were stopped at 48h or 65h of incubation. Slides were fixed, 
stained and counted via epifluorescence, as described above (see section 2.3.3) 
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Figure 20. Treatment of P. berghei liver stages did not affect the number of 
liver stage parasites. Dot plot showing the number of mature liver stages under 
different antibiotic treatments. Every point represents one well on an 8-well chamber 
slide. A) Number of liver stages 48h after infection CO= 0.01% or 1% DMSO (n = 23); 
AZ= 1 µM azithromycin (n =32); SOL10 = 10 µM solithromycin (n= 32) SOL 1= 1µM 
solithromycin (n= 6) B) number of parasites 65h after infection. CO= 0.01% or 1% DMSO 
(n= 22); AZ= 1 µM azithromycin (n= 31); SOL10= 10 µM solithromycin (n= 31) SOL 1 = 
1 µM solithromycin (n= 6). ns= non-significant, Mann-Whitney U test. Whiskers indicate 
median and interquartile range. 
Figure 20 reveals that none of the antibiotic treatments led to changes in the 
number of liver stages, neither after 48 nor after 65 hours. Outliers are due to 
inter-experimental variation (batch effect), which is shown in Figure 21: same 
colours represent a chamber slide, hence one experiment. 
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Figure 21. Analysis of outliers in the comparison of the number of P. 
berghei liver stages under antibiotic treatment. Dot plot with each colour 
representing one experiment, every data point representing a single well on a chamber 
slide. A) number of parasites 48h after infection CO= 0.01% or 1% DMSO (n = 32); AZ= 
1 µM azithromycin (n =32); SOL10 = 10 µM solithromycin (n= 32); SOL 1= 1µM 
solithromycin (n= 6) B) Number of parasites 65h after infection. CO= 0.01% or 1% DMSO 
(n= 22); AZ= 1µM azithromycin, (n= 31); SOL10= 10µM solithromycin (n= 31); SOL 1= 
1µM solithromycin (n= 6). ns= non-significant, Mann-Whitney U test. Whiskers indicate 
median and interquartile range. 
In summary, solithromycin did not affect the number of liver stage parasites within 
the HuH7 hepatocytes.  
3.2.3 Effect of solithromycin on the maturation of P. berghei liver 
stage parasites 
 
As described in material and methods (see section 2.3.3), P. berghei liver stages 
were cultured and their sizes measured after 48h and 65h of development within 
hepatocytes. 
In the beginning, experiments were undertaken with a concentration of 1% DMSO 
as control and 10 µM solithromycin solved in DMSO (resulting in a final 
concentration of 1% DMSO in solithromycin wells) 
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Figure 22. Calculated areas of P. berghei liver stages under antibiotic 
treatment with 1 % DMSO as a control.  Dot plot comparing calculated areas of 
liver stage parasites under different antibiotic treatments. Every point represents one 
liver stage parasite. A) Sizes of parasites after 48h. CO= 1% DMSO (n= 17); AZ= 1 µM 
azithromycin (n= 17), SOL = 10 µM solithromycin (n= 15). B) Sizes of parasites after 65h. 
CO= 1 % DMSO (n= 23); AZ= 1 µM azithromycin (n= 22); SOL = 10 µM solithromycin 
(n= 26). ns= non-significant, *** p< 0.0001, student’s t-test. Whiskers indicate mean and 
SD. 
Demonstrated in Figure 22, treatment with azithromycin did not affect the sizes 
of developed parasites after 48h of development but after 65h. However, there 
was a significant difference in sizes of solithromycin treated parasites in the 
earlier time point, but not after 65 hours of development. 
It is known that DMSO not only has a cytotoxic effect but can also intensify the 
cytotoxicity of drugs. Additionally, it has a modulating effect on HuH7 cells (Liu et 
al., 2015). Therefore, I changed the concentration of DMSO concentration in the 
solithromycin treated group and consequently, the control group, for subsequent 
experiments to 0.01%. Furthermore, I also lowered the concentration of 
solithromycin to see if the concentration of the compound plays a role in this 
observation. 
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Figure 23: Sizes of P. berghei liver stages under antibiotic treatment with 
0.01 % DMSO as control. Dot plot comparing measured sizes of liver stage parasites 
under different antibiotic treatments. Every dot represents one liver stage parasite. A) 
Sizes of parasites after 48h CO= 0.01% DMSO, (n= 66); AZ= 1 µM azithromycin (n= 60); 
SOL 1= 1 µM solithromycin (n= 61); SOL 10= 10 µM solithromycin (n= 62) B) sizes of 
parasites after 65h. CO= 0.01 % DMSO (n= 50); AZ= 1 µM azithromycin (n= 55); SOL 
1= 1 µM solithromycin (n= 54); SOL 10= 10 µM solithromycin (n= 56). ns= non-
significant. ***p<0.0001, **p<0.01, Mann-Whitney test. Median with interquartile range 
given. 
Figure 23 shows the sizes of liver stages at the two time points. Again, my results 
from the earlier timepoint show that parasites treated with 10 µM solithromycin 
were significantly smaller compared to the control group. However, after 65 hours 
of development, every antibiotic treatment causes a significant difference in the 
sizes of measured parasites. Furthermore, the distribution of sizes is affected by 
antibiotic treatment after 65 hours of development with absence of large 
parasites. Treatment with 10 µM solithromycin affects parasites’ sizes after 48 
and 65 hours of development. Whereas the lower concentration of 1 µM 
solithromycin, as well as the treatment with 1 µM azithromycin, merely shows 
reduced sizes of liver stages after 65 hours of exposure. 
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3.2.4 Effect of DMSO concentration on P. berghei liver stage 
parasites  
Since decreasing the concentration of DMSO from 1% to 0.01% resulted in 
different outcomes, I was interested in comparing the same antibiotic treatment 
conditions with respect to the DMSO concentration.  
 
Figure 24. Different DMSO concentrations did not influence the number of 
liver stage parasites. Dot plot comparing liver load under different experimental 
conditions. Capital letters= experiments with 1% DMSO as control and solithromycin 
solvent, small letters= experiments with 0.01% DMSO. every dot represents a liver stage 
parasite A) number of parasites after 48h of development CO= 1% DMSO (n=11); co= 
0.01% DMSO (n=10); AZ= 1 µM azithromycin while control 1% DMSO (n= 17); az= 1µM 
azithromycin while control 0.01% DMSO (n=12); SOL= 10 µM solithromycin and 1% 
DMSO concentration (n=17) sol= 10µM solithromycin and 0.01% DMSO (n=15) B) 
number of parasites after 65h of development. CO= 1% DMSO (n=10); co= 0.01% 
DMSO (n=12); AZ = 1 µM azithromycin while control 1% DMSO (n= 16); az= 1µM 
azithromycin while control 0.01% DMSO (n=16); SOL= 10 µM solithromycin and 1% 
DMSO concentration (n=16) sol= 10µM solithromycin and 0.01% DMSO (n=15). ns= 
non-significant, Mann-Whitney test. Whiskers indicate median and interquartile range. 
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Figure 25. DMSO concentration had an influence on sizes of liver stage 
parasites.  Dot plot comparing sizes of liver stage parasites under different 
experimental conditions. Capital letters= experiments with 1% DMSO, small letters= 
experiments with 0.01% DMSO, every dot represents a liver stage parasite A) Sizes of 
parasites after 48h of development. CO= 1% DMSO (n=17); co= 0.01% DMSO (n=66); 
AZ= 1 µM azithromycin while control 1% DMSO (n= 17); az= 1µM azithromycin while 
control 0.01% DMSO (n=60); SOL= 10 µM solithromycin and 1% DMSO concentration 
(n=15) sol= 10µM solithromycin and 0.01% DMSO (n=62) B) sizes of parasites after 65h 
of development. CO= 1% DMSO (n=23); co= 0.01% DMSO (n=50); AZ= 1 µM 
azithromycin while control 1% DMSO (n= 22); az= 1 µM azithromycin while control 0.01% 
DMSO (n=55); SOL= 10 µM solithromycin and 1% DMSO concentration (n=26) sol= 10 
µM solithromycin and 0.01% DMSO (n=56). ns= non-significant, *p<0.1, **p<0.01, 
***p<0.001, Mann Whitney and student’s t-test. Whiskers indicate median and 
interquartile range. 
As Figure 24 and 25 demonstrate, different DMSO concentrations did not 
influence parasite load in the liver but the individual sizes of the parasites while 
outliers again could be due to experimental repetition. Liver stage parasites in the 
control group with 0.01% DMSO were significantly smaller after 48h of 
development, but there was no difference at the later timepoint.  
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The azithromycin treatment also showed a significant difference: after 48h 
parasites were smaller in the 0.01% DMSO concentration setup, however after 
65h of development they were significantly bigger in the 0.01% DMSO solution. 
In contrast, solithromycin treatment in 0.01% DMSO resulted in larger parasites 
after 48h than in 1% DMSO. However, at 65h this difference was turned upside 
down, as parasites exposed to solithromycin in 0.01% DMSO were smaller in 
comparison to parasites exposed to the same concentration of solithromycin in 
1% DMSO. 
From this data, I conclude that DMSO concentrations had an inconsistent impact 
on the sizes of liver stage parasites.                  
3.2.5 Morphological changes of the apicoplast induced by 
solithromycin exposure 
 
While its inheritance, the apicoplast of a Plasmodium parasite assumes a 
branching structure in order to distribute to every daughter cell 1:1. Therefore, P. 
berghei liver stages were stained 65 hours after infection as described above 
(see section 2.3.3) to visualise the apicoplast. 
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Figure 26. Visualisation of P. berghei liver stages 65 hours after hepatocyte 
infection shows a defect in the biogenesis of the apicoplast within 
solithromycin treated parasites. Parasites were stained with Hoechst for DNA 
staining, anti-HSP70 antibody to visualise the parasite itself (cytoplasm) and anti-PbACP 
serum to stain the apicoplast within the parasite. Treatment with azithromycin and 
solithromycin caused an arrest of apicoplast biogenesis in comparison to the control that 
shows a normal branching structure at this time point of development. Scale bars 10 µM. 
Visualised in Figure 26, treatment with the bacteriostatic antibiotics azithromycin 
and solithromycin appears to block apicoplast biogenesis within the parasite after 
65h of development. In the control group, the organelle displays the typical 
branching structure whereas antibiotic treated parasites remain with a punctuated 
apicoplast. This leads to the speculation that the tested antibiotics inhibit the 
inheritance of the prokaryotic organelle within the parasite: the apicoplast might 
not be distributed to every merozoite developing in a liver schizont 
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 Infectivity of merosomes emerging from solithromycin 
treated Plasmodium berghei liver stage parasites 
My results of the in vitro experiments identified the apicoplast as the target 
organellar structure of solithromycin.  
To continue, the effect of solithromycin on liver stage merosomes and their 
infectivity in vivo was investigated. NMRI mice were infected with solithromycin 
treated merosomes, which emerged from infected HuH7 hepatocytes. 
3.3.1 Identifying the best time point of P. berghei merosome 
harvesting and occurred numbers of merosomes 
P. berghei liver stage parasites were cultured as described above (see section 
2.3.3). However, the in vivo experiment required a higher amount of sporozoites 
per well (see section 2.4.1) to harvest a suitable amount of emerging merosomes 
from the supernatant collected from individual wells. 
Table 3. Number of merosomes in two 8-well chamber slides cultured in 1% 
DMSO.  Solely after 72 h of development, a single merosome was detected in the 
supernatant of a total of 16 wells.   
Timepoint Number of merosomes 
65 h 0 
70 h 0 
72 h 1 
 
The first attempt for selecting the correct timepoint for harvesting the maximum 
amount of merosomes was undertaken with DMEM medium containing 1% 
DMSO. However, there was no merosome in the supernatant of two 8-well 
chamber slides after 65 h or 70 h of parasite development. I found one single 
merosome emerging from a total of 16 wells after 72 hours. 
To see whether the DMSO concentration had an impact on this observation, I 
repeated the experiment with an 8-well chamber slide of which four wells 
contained pure DMEM medium as control. 
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Table 4. Number of occurred merosomes in one 8-well chamber slide 
cultured in either DMEM supplemented with 1% DMSO or DMSO-free DMEM. 
In pure DMEM medium, merosomes emerged both earlier and in a higher number than 
in the four wells containing DMEM supplemented with 1% DMSO.  
Timepoint 
 
Number of merosomes in 4 
wells containing 1% DMSO 
Number of merosomes in 4 
wells containing pure DMEM 
70 h 0 139 
72 h  8 + 15 
 
The data presented in Tables 3 and 4 show that 1% DMSO had a great impact 
on the numbers of merosomes and the time point of when they are released into 
the supernatant. Consequently, I decreased the concentration of DMSO for the 
control group as well as for the different treatments to 0.01%. 
3.3.2 Morphology and number of merosomes emerging from P. 
berghei liver stage cultures exposed to solithromycin 
While harvesting the emerged merosomes from the supernatant I observed that 
exposure of cultured P. berghei liver stages to solithromycin had an impact on 
the morphology and quantity of emerging merosomes. 
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Figure 27. Treatment with solithromycin alters merosome formation 
(morphology and quantity). Comparison of measured concentration and 
appearance of merosomes emerging from treated and non-treated liver stage parasites 
at two different time points. Scale bars 10 µm. 
As Figure 27 illustrates, 70 hours post hepatocyte infection, merosomes, which 
emerged from liver stages cultured in the presence of solithromycin, were smaller 
and their number in the supernatant was lower compared to control cultures. 
Additionally, the membranes of merosomes from solithromycin exposed cultures 
appeared to be less well defined and the merozoites themselves seemed to be 
condensed. 75 hours after hepatocyte infection, merosomes from solithromycin 
exposed cultures appeared empty. I observed the same phenotype also for 
different, including earlier, timepoints (65h p.i., 72h p.i., 77h p.i., data not shown). 
3.3.3 Infectiousness of P. berghei merosomes from solithromycin-
exposed liver stage cultures in NMRI mice  
Next, I asked myself whether merosomes harvested from solithromycin exposed 
liver stages are infectious. To address this question, I injected a fixed amount of 
merosomes into the tail vein of malaria naïve female NMRI mice. By using a very 
thin insulin syringe (30G), I ensured that merosomes would be mechanically 
ruptured and therefore, merozoites could be released. Merosomes were 
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harvested from liver stages cultured under control conditions (0.01% DMSO) or 
cultured in 10 µM of solithromycin. Parasitaemia of mice was monitored daily via 
microscopic assessment of Giemsa stained thin blood smears. 
  
Figure 28. Kaplan-Meier analysis of time to blood stage patency in NMRI 
mice challenged with merosomes harvested from solithromycin exposed 
liver stage cultures.  NMRI mice were infected with merosomes harvested from liver 
stage cultures exposed to either 10 µM solithromycin (all merosomes harvested from 23 
wells were injected) or 0.01% DMSO (all merosomes harvested from 8 wells were 
injected). Parasitaemia was monitored via daily thin blood smears. 1) Mice infected with 
untreated merosomes (n= 5, 410 merosomes respectively) became patent after 6 or 7 
days whereas mice infected with merosomes from solithromycin treated liver stage 
cultures (n=3, 210 merosomes respectively) did not develop parasitaemia. 2) Repetition 
experiment. Mice infected with untreated merosomes (n= 5, 440 merosomes 
respectively) became patent after 5 or 6 days whereas mice infected with merosomes 
from solithromycin exposed liver stage cultures (n=3, 424 merosomes respectively) 
remained free of parasitaemia.Figure 28 shows the parasitaemia progress of NMRI 
mice infected with either treated or control liver stage merosomes. It is shown 
that injection of merosomes, emerging from with solithromycin treated liver stage 
parasites, is not followed by blood stage infection. Hence, these merozoites are 
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in contrast to naïve merosomes not able to infect erythrocytes and therefore do 
not cause malaria symptoms.  
Solithromycin inhibits the capacity of F1 progeny P. berghei merozoites emerging 
from exposed liver stage cultures to infect erythrocytes. 
 Effect of primaquine conjugated to hepatitis B Virus 
surface derived PreS-peptide on P. berghei liver stages 
cultured in transgenic human hepatoma cells that 
constitutively express NTCP  
A potential strategy to gain liver specific transportation is based on the discovery 
of the peptide domain (PreS1) of the hepatitis B virus surface antigen that 
mediates highly specific binding to the sodium taurocholate co-transporting 
polypeptide (NTCP) on the surface of hepatocytes (see section 1.7). 
This liver specific transportation is interesting for the use in whole organism 
vaccinations. The conjugated drugs could be applied simultaneously with the 
parasites and be delivered specifically to the liver. This could result in less 
systemic adverse side effects, dose reduction of the drug and improvement of 
patients’ compliance. 
To study the effectiveness of a PreS-conjugated drug regarding the usage in 
whole organism vaccination, I used a well-studied and known anti-malarial which 
is called primaquine. Besides the interesting usage of PreS-conjugated drugs in 
whole organism vaccinations, this drug also shows severe adverse side effects 
(see section 1.8), which could be reduced using the conjugated drug. 
Before embarking on in vivo experiments, I initially aimed to establish the potency 
of PreS1-conjugated drugs in transgenic hepatocytes that constitutively express 
NTCP. 
In this experiment, I used primaquine that had been chemically conjugated to the 
PreS1. Since human hepatoma cell lines do not express the PreS1 receptor 
NTCP, I used a transgenic hepatocyte cell line that constitutively expresses 
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NTCP. After infection of hepatocytes with P. berghei ANKA sporozoites (see 
section 2.3.3) liver stage parasites were exposed to 10 µM of PreS1-conjugated 
primaquine. 10 µM primaquine served as a positive control, 0.01% DMSO as a 
negative control (see section 2.3.3). 
Liver stage parasites treated with primaquine show an early arrest of 
development. Treatment with primaquine results in smaller parasites but the 
same number of parasites in the liver (Putrianti et al., 2009a). 
3.4.1 Analysis of P. berghei liver stage development under exposure 
to PreS1-conjugated primaquine 
 
Figure 29.  Treatment with primaquine or PreS1-conjugated primaquine did 
not affect the number of P. berghei liver stages.  Dot plot comparing parasite 
numbers under different treatments. A) 48h after hepatocyte infection with following 
treatments: CO= 0.01% DMSO (n= 6), PQ = 10 µM primaquine (n= 6), PreSPQ= 10 µM 
PreS1-conjugated primaquine (n= 12). B) 65h after hepatocyte infection with following 
treatments: CO= 0.01% DMSO (n= 4), PQ= 10 µM primaquine (n= 4), PreSPQ= 10 µM 
PreS1-conjugated primaquine (n= 8). ns= non-significant, Mann-Whitney U test. 
Whiskers indicate median with interquartile range. 
As Figure 29 shows, there was no significant difference in the overall number of 
liver stage parasites between control and primaquine, or control and PreS1-
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conjugated primaquine treatment at 48h or 65h after hepatocyte infection. Hence, 
PreS1-conjugated primaquine did not affect the liver load of P. berghei parasites. 
3.4.2 Effect of PreS1-conjugated primaquine on the size of P. 
berghei liver stage parasites 
 
Figure 30. Both primaquine and PreS1-conjugated primaquine treatment 
affected the sizes of liver stage parasites but the effect was more 
pronounced for unconjugated primaquine.  Dot plot comparing the calculated 
areas of P. berghei liver stages under different drug treatment. Each dot represents a 
liver stage parasite. A) After 48h of development. CO= 0.01% DMSO (n= 53), PQ= 10 
µM primaquine (n= 53) PreSPQ= 10 µM PreS1- conjugated primaquine (n= 55)   B) After 
65h of development. CO= 0.01% DMSO (n= 59) PQ= 10 µM primaquine (n= 51) 
PreSPQ= 10 µM PreS1- conjugated primaquine (n=57). *** p < 0.001, ** p < 0.0, Mann-
Whitney U test. Whiskers indicate median and interquartile range. 
As shown in Figure 30, exposure of liver stage cultures to primaquine led to 
dramatically reduced sizes of parasites at both time points (early arrest). PreS1-
conjugated primaquine also had an impact on the size of developed liver stage 
parasites. However, compared to primaquine the effect of PreS1-conjugated was 
much less pronounced, indicating a failure of the conjugate to release its cargo 
(primaquine) into the P. berghei-infected host cell. 
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4 Discussion 
Probably the best instrument to contain and eventually eradicate malaria 
worldwide is an effective vaccination. Even though there have been several 
achievements to accomplish this goal there is still the need for further 
development. 
Whole organism vaccinations using antibiotic-attenuated Plasmodium parasites 
are already known to induce sterile immunity against reinfection with the same 
strain. Antibiotics targeting the apicoplast, a prokaryotic organelle within the 
parasite, are suitable candidates (see section 1.6). However, safe and effective 
compounds are needed for further development. Strategies to specify the 
transportation of these antibiotics to the liver could additionally extend the already 
achieved success. 
 Solithromycin’s mode of action against Plasmodium 
spp. regarding its usability for a whole organism 
vaccination 
Solithromycin (characterised above, see section 1.6.2) could offer a new 
possibility for an antibiotic attenuated whole organism vaccine candidate due to 
its special chemistry and efficacy. Regarding the usability for an attenuation of 
Plasmodium parasites, I focused on certain characteristics of its mode of action. 
4.1.1 Effect of solithromycin on P. falciparum blood stage parasites 
To begin, I used the compound on P. falciparum blood stage merozoites. I was 
able to certify the effect of my compound by testing the already published IC50 
and IC99 (Wittlin et al., 2012). As Wittlin et al. describe, solithromycin leads to a 
delayed death in Plasmodium blood stage parasites, which was the conclusion 
of my experiments as well. It is already known that bacteriostatic antibiotics stop 
the growth of Plasmodium parasite cultures after their second cycle of blood 
stage development due to their inhibition of the apicoplast’s inheritance (Ramya 
et al., 2007). 
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I was also able to demonstrate that the compound did not inhibit erythrocyte 
invasion of merozoites. This was discussed for the macrolide azithromycin by 
Wilson et al. in 2015 (Wilson et al., 2015). However, I used the known 
concentrations of solithromycin for P. falciparum 3D7 treatment resulting in 
delayed death (see section 2.2.2). In the experiments of Wilson et al. a 760 fold 
higher concentration of azithromycin than typically used for the delayed death 
assay lead to invasion inhibition (Dahl and Rosenthal, 2007). Since I did not use 
these high concentrations, which probably cannot be achieved in vivo, I cannot 
exclude an inhibitory effect of solithromycin on P. falciparum blood stage 
merozoites using the experimental setup Wilson et al. used.  
To validate the indication that solithromycin affects the prokaryotic organelle 
within the parasite, I used the compound on synchronised P. falciparum 3D7 ring 
stages lacking the apicoplast. As De Risi and Yeh presented, blood stage 
parasites only depend on the apicoplast for its IPP production (Yeh and DeRisi, 
2011). Depletion of the apicoplast was achieved by treating parasites of the lab 
strain 3D7 with clindamycin while supplementing IPP over a certain period of 
time. Apicoplast free blood stage parasites are then able to survive only due to 
IPP supplementation.  
P. falciparum parasites without apicoplast but supplemented with 100 µM IPP 
were not affected by solithromycin, hence showed the same development as the 
positive control treated with clindamycin (known to target the apicoplast) + 100 
µM IPP. 
In contrast to the apicoplast containing lab strain 3D7 treated with solithromycin. 
The treated 3D7 strain showed the typical delayed death: parasites under 
treatment were not able to develop further than a second cycle of erythrocyte 
invasion assuming an inhibition of apicoplast biogenesis (see section 1.3.2). 
Since parasites lacking the apicoplast have been rescued by supplementing IPP 
under solithromycin treatment, I assumed an impactful effect of the compound on 
solely the apicoplast and no other structure within the parasite.  
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I also noted that the apicoplast containing 3D7 strain developed faster than 
typically observed (Trager and Jensen, 1976) while the apicoplast free P. 
falciparum 3D7 parasites were slightly delayed in their development, which is 
contrary to previous studies (Yeh and DeRisi, 2011). This could be due to the 
experimental condition. I used synchronised ring stage parasites as a starting 
point in this experimental setup. In this case, contrary to the use of merozoites as 
a starting point, it is very difficult to state exactly how far the different ring stages 
were developed. The 3D7 ring stages containing an apicoplast could have been 
slightly older and therefore result in faster development. Also, the fact that I used 
an apicoplast free parasite culture already adapted to a titrated concentration of 
IPP for rescuing could have played a role. I used an IPP concentration of 100µM 
to achieve a vivid parasite culture. However, Yeh and DeRisi showed in their 
paper the need for 200µM supplementation of IPP for optimal development. The 
concentration I used could have been enough for parasite survival but may be 
slightly too low for the known speed of development. Additionally, this observation 
could be different in further repetitions of the experiment. Since it was on main 
interest if the apicoplast free parasites treated with solithromycin were able to 
fulfil a third cycle of development in general, I did not focus on the also interesting 
aspect of speed of development any further. 
Summarising, solithromycin affects the biogenesis and inheritance of the 
apicoplast of P. falciparum blood stage parasites in their second cycle of 
development. This mode of action is comparable to several other antibiotics (Dahl 
and Rosenthal, 2007). 
4.1.2 Effect of solithromycin on P. berghei liver stage parasites 
To continue my investigations, I focused on an earlier stage of the parasite’s life 
cycle. I used P. berghei, a rodent malaria parasite, to explore the liver stage of 
Plasmodium parasites. The aim of this study is to explore the effect of 
solithromycin on the apicoplast in Plasmodium parasites. Since host-parasite 
interaction does not play a role but solely the biological effect of the antibiotic on 
the parasite and especially its prokaryotic organelle, findings in P. berghei can be 
transferred easily to human pathogen Plasmodium species. 
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Demonstrated in murine models by Butler et al., late liver stage arrested parasites 
led to better protection against reinfection than earlier elimination of the parasite 
from the liver due to enlarged CD8+ t cell reaction (Butler et al., 2011). Therefore, 
I focused on the effect of solithromycin regarding the timepoint of liver stage 
arrest and its target within parasites. 
The first stage of the parasites’ lifecycle, sporozoites and their entering of the liver 
parenchyma, was also the first object of interest. Incubation with solithromycin 
prior hepatocyte invasion did neither affect the invasion rate of treated 
sporozoites, nor the total number of developed liver stage parasites after 65 hours 
compared to the control group. Hence, solithromycin does not stop the parasite’s 
development at this early point but allows further development in the liver and 
duration of infection, consequently further antigen presentation to the host’s 
immune system. Like already mentioned, comparable to the effect of 
azithromycin and chloroquine (see section 1.6). 
In comparison to the following experiments using not preincubated sporozoites, 
the overall liver load of the invasion assay was lower than without incubation of 
sporozoites before entering the liver. Since the fragile sporozoites were incubated 
with the compound for one hour before they were added to the Huh7 hepatoma 
cells, there certainly was a partial loss of sporozoites in this time interval. 
However, since the amount of invaded pre-incubated sporozoites in the control 
group was lower as well, the compound did not show an inhibiting effect on 
invasion.  
Following the parasites’ life cycle, I monitored solithromycin’s effect on P. berghei 
liver stage parasites. Azithromycin was used as a positive control. Previous 
studies showed that an increased liver load (which is also related to the 
application of parasites) correlates with better protection against reinfection using 
whole organism vaccinations (Nganou-Makamdop et al., 2012a).  
None of the antibiotic treatments influenced the overall number of liver stages 
after both, 48 and 65 hours. However, some outliers appeared which were due 
to experimental repetition. In every experiment, different sporozoites dissected 
from various Anopheles mosquitos were used. Some seem to be more potent in 
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invasion than others. Not only biological individuality but also the difference 
between several repetitions of the experiment regarding processing time of 
sporozoites from dissection out of mosquitos until invasion of hepatocytes could 
play a role.  
Giving particular attention to the measured sizes of P. berghei liver stage 
parasites, a new aspect was presented: DMSO concentration. Azithromycin was 
solved in distilled H2O. But since solithromycin was solved in DMSO, I chose the 
concentration of DMSO in the control group adaptively to the concentration of the 
chemical in the solithromycin group, which was eventually a concentration of 1 % 
DMSO.  
With this experimental setup, I observed an inconsistent effect of the two 
antibiotics used: Parasites treated with azithromycin showed no defect in growth 
after 48 hours but after 65 hours of development. This was opposed to treatment 
with solithromycin which showed a defect of growth after 48 hours but not after 
65 hours of development. Different possible reasons for this observation exist: 1) 
solithromycin could solely lead to a delay in the growth of parasites in the liver 
while not affecting the total number or the final size. 2) As already published, 
azithromycin targets the apicoplast within the liver stage parasite (Friesen et al., 
2010). As described before (see section 1.3), this organelle assumes a branching 
structure while distribution to developed daughter cells in a liver schizont. Lacking 
this organelle and its expansion, parasites could be affected in their size. 
However, solithromycin is strongly expected to use the apicoplast as a target as 
well, hence should lead to a decrease of size as well. 3) As mentioned previously 
(see section 3.2), DMSO has different adverse effects. In comparison to 
solithromycin, azithromycin was solved in solely distilled H2O and therefore 
azithromycin treated parasites were not influenced by DMSO. Solithromycin 
however, solved in DMSO, is a substrate of cytochrome P 3A4 which is induced 
by DMSO (Still et al., 2011). Induction of cytochrome could lead to a faster 
elimination of solithromycin within the cells and therefore a faster decrease of 
concentration. Additionally, DMSO intensifies cytotoxic effects. These aspects 
could provide an explanation for diverse data in the control and solithromycin 
group. 
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In order to counter the bias, I changed the concentration of DMSO into 0.01%. I 
additionally applied a lower concentration of solithromycin with regard to 
cytotoxicity. Even with a decreased concentration of DMSO, treatment with 10 
µM solithromycin led to significantly smaller liver stage parasites after 48 hours 
of development in contrast to treatment with azithromycin and 1 µM solithromycin. 
Cytotoxicity of 10 µM solithromycin could result this outcome by targeting not only 
the apicoplast but also other structures of the liver stage parasite in this high 
concentration. However, to date, there are no published data about the 
compound’s hepatocytotoxicity in vitro. Yet, solithromycin is not approved 
because the FDA criticises the lack of evidence of its clinical safety regarding 
possible liver toxicity in vivo likewise its predecessor telithromycin (Abdulla, 
2016). However, in phase III clinical trials the compound was declared to be safe 
and telithromycin’s adverse side effects were attributed to a pyridine side chain 
(see section 1.6.2) which does not exist in solithromycin’s configuration 
(Fernandes et al., 2016, Jamieson et al., 2015). Nevertheless, further 
experiments concerning cytotoxicity in vitro and vivo are indispensable.  
Having a look at the later time point under these conditions, every treatment was 
followed by development of significantly smaller liver stage parasites, even the 
parasites treated with solithromycin 10µM, in contrast to the experimental set up 
with DMSO 1%. This could again be explained by the cytochrome induction of 
DMSO in a higher concentration and the lack of the apicoplast due to treatment 
with azithromycin as well as solithromycin.  
Since I monitored different results of matured sizes of P. berghei liver stage 
parasites by changing the concentration of DMSO, I compared the different 
experimental conditions concerning the DMSO concentration and appearance of 
developed parasites. Higher concentration of DMSO did not affect the overall 
number of parasites developed in the liver. The occurred sizes varied very 
inhomogeneously as described and discussed above. However, since 
azithromycin was not solved in DMSO but in distilled H2O and showed significant 
differences of sizes in the compared experiments as well, it seems reasonable to 
suppose that not solely the concentration of DMSO influenced the sizes of liver 
stages but also other logistical reasons. Individuality of parasites and HuH7 cells, 
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processing time, measurement errors plus experimental repetition as an 
independent variable could have played a role.   
However, with respect to the median of parasites’ sizes, the difference between 
the control group and azithromycin or 1 µM solithromycin treated parasites are 
respectively approximately around 50 µm², between the control group and 
parasites treated with10 µM solithromycin approximately around 80 µm². 
Table 5. Comparison of medians of liver stage parasites’ sizes after 65h of 
development 
TREATMENT MEDIAN DIFFERENCE TO 
CONTROL 
Control (0.01% DMSO) 267.3 µm²  
Azithromycin 215.6 µm² 51.7 µm² ( - 19%) 
Solithromycin 1 µM 216.1 µm² 51.2 µm² ( -19 %) 
Solithromycin 10 µM 187.0 µm² 80.3 µm² (- 30%) 
 
The presented differences of measured sizes are, considering biology, of no 
significant consequence regarding antigen presentation hence a whole organism 
vaccination. Especially because parasites are alive and metabolic active. Though 
further investigations of presented antigens while development, like the 
extensively studied SpzCSP, might lead to other interesting insights (Kumar et 
al., 2006).  
Demonstrated before, solithromycin targets the apicoplast in P. falciparum blood 
stage parasites. Relating to my interest of solithromycin inhibiting the apicoplast 
in liver stage parasites likewise, I presented via immunofluorescence assay the 
lack of the branched organelle in solithromycin treated liver stage parasites after 
65 hours of development. There was no apicoplast distribution to daughter cells. 
At this point, solithromycin’s mode of action on Plasmodium parasites is similar 
to azithromycin’s effect (Friesen et al., 2010). This underlines its abilities as a 
candidate for the chemical attenuation of parasites. 
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4.1.3 Solithromycin’s effect on the infectivity of P. berghei liver stage 
merozoites 
 Whereas DMSO concentration of 1% did not show a stable effect on liver stage 
parasites, it completely inhibited the emerge of merosomes out of hepatocytes. 
Solithromycin treated sporozoites developed to liver stage parasites within 65 
hours with no difference in appearance compared to the control group. Hence 
these parasites represent metabolic active cells. There was exclusively a defect 
in emerging merosomes in the wells’ supernatant, which is to date not described 
in literature. This finding could be due to DMSO’s effect of loosening cell 
membranes (de Menorval et al., 2012). The parasite requires the host hepatocyte 
to build up merosomes, the membrane of these daughter cell packed vesicles 
consists of the host’s cell membrane (Sturm et al., 2006). Hence, the parasite 
might not be able to build up the merosome membrane under the influence of 
high concentrations of DMSO. 
Accompanying this information, I changed the concentration of DMSO from 1% 
to 0.01%. The decrease of concentration led to an increase of merosome 
appearance in the control group. However, I was able to show the altering effect 
of solithromycin on merosome formation and occurred concentration.  Moreover, 
merosomes emerging from treated parasites were not infective. After i.v. injection 
into mice, merosomes emerging from solithromycin treated parasites were not 
able to infect erythrocytes and thus did not lead to parasitaemia. 
Since the experimental setup and harvesting of merosomes under treatment 
condition was accompanied by a lower concentration of occurred merosomes, I 
was not able to inject the exact same number of parasites into mice of the two 
groups. In my first experiment, I injected a lower number of solithromycin treated 
parasites (all merosomes out of 8 wells, 210 respectively) into mice than into the 
control group (all merosomes out of 8 wells, 410 respectively) which could also 
explain parasitaemia free animals. However, much less numbers of merosomes 
(100) were shown to result in blood stage infection after using the same injection 
strategies I used (Friesen et al., 2010). Hence, the injection of 210 merosomes 
should lead to a blood stage infection if merosomes were infectious. Moreover, I 
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was able to inject approximately the same amount of merosomes in both groups 
in a repetition experiment resulting in the same outcome. 
There are several modifications or knock-outs of genes of the parasite which are 
proven to change merosome formation regarding number or delay in occurrence 
of merosomes. Some of these affected structures are located in the 
parasitophorous vacuole, like a phospholipase (PbPL), serine kinases or the 
protein EXP-1. There are also enzymes associated with merozoites’ nuclei like 
the serine kinase SUB1 (Burda et al., 2015, Suarez et al., 2013). 
Additionally, and in this case much more interesting, there are relevant proteins 
of the apicoplast, of which knockouts lead to fewer or even lack of merosomes, 
close to what I observed under solithromycin treatment. These proteins are widely 
spread in the different sections of the apicoplast’s functions:  
For example, there is NFUapi, which is crucial in an iron-sulfur cluster or PALM 
which plays an important role in only liver stage parasites but does not influences 
apicoplast segregation (Haussig et al., 2011, Haussig et al., 2013). Moreover, a 
protein called Fabl in the fatty-acid pathway and a liver specific protein called 
LISP2 which is exported into the cytoplasm of the hepatocyte for merozoite 
formation play an important role (Orito et al., 2013, Yu et al., 2008). 
The loss of these proteins results in a significantly lower number of occurred 
merosomes. However, the merozoites emerging are infective, which means they 
are able to invade erythrocytes and cause malaria symptoms. This is in contrast 
to my results, showing that solithromycin treated merosomes were not infective, 
likewise, merosomes emerging from azithromycin treated parasites (Friesen et 
al., 2010). Additionally, the observance of solithromycin resulting in delayed 
death in blood stage parasite assumes targeting of housekeeping functions and 
no influence on metabolic pathways within the apicoplast. 
To date, one cannot find a description of antibiotics leading to a decrease in the 
number of formed merosomes in literature. Additionally, there is no reference of 
a treatment causing structural deficits of merosomes. My basic observance 
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certainly demands further experiments focusing on the structural deficits and 
decreased number of occurred merosomes. 
Still, concerning biological consequences, emerging of uncontagious merosomes 
as a result of solithromycin treatment is exactly what is asked for a CAS 
vaccination approach. However, I neither investigated the immediate response of 
the rodents’ immune system, nor the probably build immunity after injection of 
uninfectious P. berghei merosomes. But since the requested effect was shown 
after the same experimental setup for azithromycin, it can be assumed that 
inoculation of solithromycin treated merosomes result in protection against 
reinfection with the same strain as well (Friesen et al., 2010). 
 Effect of PreS1-primaquine on P. berghei hNTCP Huh7 
liver stage parasites  
The second aim of this study was to test PreS1-conjugated primaquine on P. 
berghei liver stages to verify or disprove a liver specific effect of the compound 
due to distinct transportation to the liver. 
Described above (see section 1.7.2) the preS1 surface protein of the hepatitis B 
virus was already used for liver specific transportation. Stephan Urban’s working 
group established and kindly provided a peptide conjugation of PreS1 and 
primaquine, to test whether this liaison could lead to liver specific delivery of the 
antimalarial compound. Hence, enhance the effect of primaquine on liver stage 
parasites while reducing the systemic adverse effects. Thus, I compared 
unconjugated vs. conjugated primaquine with respect to its impact on the 
development of P. berghei liver stage parasites. 
Primaquine’s mode of action, eliminating or rather causing nonviable liver stage 
parasites, was already described by Putrianti et al. and confirmed my results 
(Putrianti et al., 2009b). The liver load of parasites in the two treatment groups 
did not differ from the control however there was a difference in parasites’ sizes 
in data of both measured time points as described above (see section 3.4).  
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Table 6. Comparison of medians of liver stage parasites’ sizes after 48h of 
development 
TREATMENT MEDIAN  DIFFERENCE TO CONTROL 
Control 208.0 µm²  
Primaquine 46.56 µm² 162,44 µm² (- 77,65%) 
PreS1-primaquine 145.1 µm² 62,9 µm² (- 30%) 
 
Table 7. Comparison of medians of liver stage parasites’ sizes after 65h of 
development 
TREATMENT MEDIAN  DIFFERENCE TO CONTROL 
Control 212.7 µm²  
Primaquine 56.0 µm² 156 µm² (- 73,7 %) 
PreS1-primaquine 179.7 µm² 32,3 µm² ( -16 %) 
 
As shown in Table 6 and 7, the smallest parasites were measured after treatment 
with primaquine, the differences of 162,44 µm² after 48 hours of development and 
156 µm² after 65 hours demonstrate a strong impact on the maturation of liver 
stage parasites. Primaquine treatment reduced the area of parasites by 
approximately 75%. 
In contrast to this observation, even though the treatment with PreS1-conjugated 
primaquine reduced the measured sizes of liver stages as well, there was a minor 
impact. Sizes were reduced by 30% at the earlier time point and even less (16%) 
after 65 hours of liver stage development. As described above (see section 3.2), 
differences in size followed by PreS1-conjugated primaquine treatment might not 
play a role regarding biology and assume that viable parasites remained after 
treatment. 
I expected the conjugation to show an equal or even enhanced effect of 
primaquine but unfortunately, the peptide conjugation of PreS1 and the 
antimalarial drug did not show the expected effect. Thus, did not lead to a liver 
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specific transport of primaquine, in contrast to the already published effect of a 
conjugation with pegylated liposomes and lipid nanoparticles (see section 1.7.2). 
This observation suggests that the peptide conjugation of Pres1 and primaquine 
is too strong, hence the compound is not able to loosen from the peptide and so 
remains outside hepatocytes. Since the NTCP receptor is saturated fully with 
much less than a concentration of 10µM which I used in my experiments, I would 
not expect any effect even with higher concentrations (Watashi et al., 2014b). 
Therefore, I promote further experiments based on e.g. lipid nanoparticles. 
 
 Conclusion 
To conclude, the presented results of solithromycin’s effect on Plasmodium 
parasites indicate the compound as an eligible candidate for a whole organism 
vaccination. With the apicoplast as a target, it allows liver stage parasites to 
develop into uninfectious merosomes to achieve a long antigen presentation to 
the host’s immune system without causing malaria symptoms. However, there is 
an urgent need for further studies on its safety. Furthermore, detailed 
investigations regarding the immune response of rodents after immunisation with 
solithromycin treated merosomes must be performed. Additionally, trials focusing 
on the induced immunity by antibiotic attenuated parasites, especially regarding 
cross or strain specific immunity are necessary to be able to further pursue this 
approach. 
Unfortunately, the peptide PreS1-conjugation of primaquine did not show the 
expected effect on P. berghei liver stage parasites. More promising approaches 
e.g. based on lipid nanoparticles have to be investigated further. 
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5 Summary 
Despite successful efforts to decrease suffering from malaria, the impact on 
global health still is enormous. Prevention is a key element in the fight against 
this parasitic disease. Malaria might only be contained and eventually eliminated 
worldwide by a vaccination that is affordable, safe and efficient. Whole organism 
vaccinations using antibiotic-attenuated parasites feature these potentials.  
This study comprises two different aspects. Firstly, the main interest was on 
peptide-conjugated drugs. A conjugation of drugs with the hepatitis B virus’ large 
surface antigen (PreS1), which constitutes the virus’ entry key to hepatocytes 
was tested. Not only could this conjugation be applied in one single shot with the 
parasites and thus simplify the application process of the vaccine. It could also 
lead to a specific transport of drugs to the liver and consequently result in a 
reduction in dose and minimisation of adverse side effects. PreS-conjugation with 
a well-established antimalarial, primaquine, was tested on Plasmodium liver 
stage parasites. Unfortunately, treatment with the drug conjugation did not show 
the wished-for effect and therefore needs further investigations.  
Secondly, the mode of action of the new fluoroketolid antibiotic solithromycin 
regarding the possible usage in a whole organism vaccination was investigated. 
The compound showed an effect on the apicoplast in blood and liver stage 
parasites. It could be demonstrated that solithromycin inhibits the inheritance and 
segregation of this prokaryotic organelle into the parasites’ daughter cells. 
Experiments with blood stage parasites showed the typical “delayed death” 
phenomenon. Treated liver stage parasites were arrested in a late stage of 
development, hence could induce long and various antigen stimulation of the 
host’s immune system. However, i.v. injection of treated liver stage merosomes 
in mice revealed that treated daughter cells emerging from the liver are not able 
to invade erythrocytes. Consequently, there would be no incident of malaria 
symptoms but only the establishment of protection against reinfection. 
The findings suggest that solithromycin is a suitable drug for attenuation of 
Plasmodium parasites. Therefore, I promote further investigations e.g. regarding 
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safety, immunostimulation after i.v. merosome injection and subsequently 
challenging with viable parasites for a further development of whole organism 
vaccinations against malaria.  
 
Zusammenfassung 
Trotz erfolgreicher Bemühungen, das Leiden an Malaria zu mindern, sind die 
Auswirkungen auf die globale Gesundheit immer noch enorm. Prävention ist ein 
Schlüsselelement im Kampf gegen diese parasitäre Krankheit. Malaria kann 
möglicherweise nur durch eine Impfung, die erschwinglich, sicher und effizient 
ist, eingedämmt und letztendlich weltweit eradiziert werden. Impfungen mit 
lebenden Parasiten, die mit Antibiotika abgeschwächt wurden, bieten diese 
Möglichkeiten. 
Diese Studie umfasst zwei verschiedene Aspekte.  
Als erstes lag das Interesse auf peptidkonjugierten Arzneimitteln. Es wurde eine 
Konjugation von Arzneimitteln mit dem großen Oberflächenantigen des Hepatitis-
B-Virus‘ (PreS1) getestet, das den Eintrittspunkt des Virus in Hepatozyten 
darstellt. Diese Konjugation könnte nicht nur zeitgleich als Einzelgabe mit den 
Parasiten appliziert werden und so den Verabreichungsprozess vereinfachen. Es 
könnte ebenfalls zu einem spezifischen Transport von Arzneimitteln in die Leber 
führen und folglich zu einer Dosisreduzierung und Minimierung von 
Nebenwirkungen führen. Die PreS-Konjugation mit einem bewährten 
Malariamittel, Primaquin, wurde an Plasmodiumparasiten im Leberstadium 
getestet. Die Behandlung mit der Wirkstoffkonjugation zeigte leider nicht den 
gewünschten Effekt und bedarf daher weiterer Untersuchungen. 
Als zweiter Punkt wurde die Wirkungsweise des neuen Fluorketolid-Antibiotikums 
Solithromycin im Hinblick auf die mögliche Anwendung innerhalb einer Impfung 
mit attenuierten Parasiten getestet. Der Wirkstoff zeigte einen Effekt auf den 
Apikoplasten der Parasiten im Blut- und Leberstadium. Es konnte gezeigt 
werden, dass Solithromycin die Vererbung und Segregation dieser 
prokaryotischen Organelle in die Tochterzellen der Parasiten hemmt. 
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Experimente mit Parasiten im Blutstadium zeigten das typische Phänomen des 
sogenannten „delayed death“. Behandelte Parasiten im Leberstadium wurden in 
einem späten Stadium in ihrer Entwicklung gestoppt und könnten daher eine 
lange und diverse Antigenstimulation des Immunsystems des Wirts auslösen. Die 
intravenöse Injektion von behandelten Leberstadien-Merosomen in Mäuse 
ergab, dass behandelte Tochterzellen, die aus der Leber austreten, nicht fähig 
sind Erythrozyten zu befallen. Infolgedessen würden keine Malariasymptome 
auftreten, sondern lediglich ein Schutz gegen eine erneute Infektion geschaffen. 
Die Ergebnisse legen nahe, dass Solithromycin ein geeignetes Medikament zur 
Abschwächung von Plasmodium-Parasiten ist. Daher befürworte ich weitere 
Untersuchungen, z.B. in Bezug auf Sicherheit, Immunstimulation nach i.v. 
Merosom-eninjektion und zuletzt Überprüfung des Schutzes mittels lebenden 
Parasiten, für die Weiterentwicklung einer Impfung gegen Malaria. 
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